

# BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS  
POTENTIAL OF HONG KONG'S  
BIOTECH ECOSYSTEM

# CONFERENCE

---

## DAY TWO

Thursday September 14

*Order of advertisements will be different on the printed version*

# New Horizon Health Global R&D Headquarter

On 17th February 2023, New Horizon Health has put into operation its Global R&D Headquarter in Hong Kong. Leveraging on New Horizon Health's internal STAR-seq Multi-omics technology, the Global R&D Headquarter focuses on transforming cancer screening technology achievements into applications like developing product pipelines using Next Generation Sequencing technology to promote overseas commercialization and globally synchronous clinical trials.

**HKD 100 million  
Expected  
investment in  
the next 5 years**



CUGATT  
GGTCUA  
TUGGAT  
ATTUCT  
UTATUC

**諾輝健康國際研發中心啟動儀式**

New Horizon Health International R&D Center Launching Ceremony



**First batch of  
Scientist  
recruitment  
20 - 30**

**諾輝健康國際研發中心啟動慶典**

**STAR-seq**

Leveraging on cfRNA (cell-free RNA) and ctDNA (circulating tumor DNA) fragmentomics technology, STAR-seq is New Horizon Health's pioneer molecular technology that adopts the concept of "Central Dogma" of modern molecular biology, and systematically profiles circulating DNA, RNA, and protein

**Total space of  
10,000 ft<sup>2</sup>**



Table with 2 columns: Time slots (08:30, 09:00-09:30, 09:30-09:40, 09:40-10:10, 10:10-10:35, 10:35-11:00) and Event Registration/Activity Log (EVENT REGISTRATION 活动登记, BIOHK AUDITORIUM, THE DISEASE BURDEN AND THE STRATEGY OF EARLY DIAGNOSIS OF HCC IN CHINA, KEYNOTE SPEAKER: PROF. YU WANG, KEYNOTE SPEAKER: MS. LILLIAN CHEONG, THE ROLE OF CHINA'S BIOTECH SECTOR IN GLOBAL HEALTHCARE INNOVATION, KEYNOTE SPEAKER: MS. NISA LEUNG, INNOVATIONS IN BIOTECHNOLOGY AND BIOMANUFACTURING THROUGH ENGINEERING BIOLOGY, KEYNOTE SPEAKER: PROF. AKIHIKO KONDO, GENETICS AND GENOMICS IN CANCER DRUG DEVELOPMENT, KEYNOTE SPEAKER: PROF. RAJU KUCHERLAPATI)

Main event grid with 4 columns: BIOHK AUDITORIUM, INNOVATION GALLERIA, TECHNOLOGY HALL, LOCI SQUARE. Includes sessions like 'INNOVATIONS IN CANCER RESEARCH & IMMUNOTHERAPIES', 'POTENTIAL OF SYNTHETIC BIOLOGY IN HEALTHCARE', 'UNDERSTAND YOUR MICROBE GARDEN', 'IVD CANCER SCREENING', 'REWRITE "HEALTH" WITH CELL/ GENE THERAPY', 'EXPLORE CUTTING EDGE APPROACHES TO DISEASE TREATMENT', 'INNOVATIVE HEALTHCARE', 'LUNCH BREAK 休息', 'BRACE AWARDS', 'CHINESE PHARMA GOING INTERNATIONAL', 'CHINESE MEDICINE SPECIAL PROGRAM', 'PITCHING STRATEGIES FOR BIOMEDICAL COMPANIES', 'ACON PHARMACEUTICALS', 'EMERGING ONCOLOGY COMPANIES', 'Molecular glue degrader drugs', 'First-in-Class CDH17-Targeted Immunotherapy', 'Coffee Break', 'Session 1 第一节', 'Session 2 第二节', 'Session 3 第三节', 'Panel discussion', 'Ms. Shoujun Wang', 'Mr. Yongheng Huang', 'Ms. Huihui Wang', 'Panel discussion', 'Dr. Jinyang Chen', 'Ms. Ming Yang', 'Ms. Shoujun Wang', 'Mr. Yongheng Huang', 'Ms. Huihui Wang', 'Panel discussion', 'Dr. Jinyang Chen', 'Ms. Ming Yang', 'Ms. Shoujun Wang', 'Mr. Yongheng Huang', 'Ms. Huihui Wang'

ONEZONE PARTNERING

# KEYNOTE ADDRESS

Thursday, September 14 | 09:00 AM - 10:30 AM (GMT+8)

09:00 - 09:30

**KEYNOTE SESSION : PROF. YU WANG, CHINESE FOUNDATION FOR HEPATITIS PREVENTION AND CONTROL**  
The Disease Burden and the Strategy of Early Diagnosis of HCC in China

09:30 - 10:00

**KEYNOTE SESSION: MS. NISA LEUNG (QIMING VENTURES)**

09:30 - 10:00

**KEYNOTE SESSION : PROF. AKIHIKO KONDO, VICE PRESIDENT, KOBE UNIVERSITY**

10:00 - 10:30

**KEYNOTE SESSION: PROF. RAJU KUCHERLAPTI, PAUL C. CABOT PROFESSOR GENETICS, HARVARD UNIVERSITY**  
Genetics and Genomics in Cancer Drug Development

# Science

BIOHK2023 SILVER SPONSOR

Science Magazine, published by the American Association for the Advancement of Science (AAAS), is a renowned global publication at the forefront of scientific research and discovery. With a rich history and reputation spanning over a century, Science Magazine delivers cutting-edge scientific articles, news, and expert analysis across various disciplines. It serves as a trusted source of information for scientists, researchers, and enthusiasts worldwide, providing comprehensive coverage of groundbreaking discoveries, technological advancements, and critical issues shaping the scientific community. Through its online and print platforms, Science Magazine continues to inspire and inform readers, fostering curiosity and advancing the frontiers of knowledge.

由美國科學促進會（AAAS）出版的《科學》雜誌是全球知名的學術期刊，在科學研究和發現方面處於前沿。《科學》雜誌擁有一個多世紀的歷史和聲譽，以提供高水平的科學文章、新聞和專家分析，以涵蓋各種學科。它是全球科學家、研究人員和愛好者可信賴的信息來源，全面報導了重大發現、技術進步和科學界塑造的重要問題。通過其在線和印刷平台，《科學》雜誌繼續鼓勵和通知讀者，激發他們的好奇心，推動他們向第一線的知識領域邁進。



HONG KONG-SHENZHEN  
INNOVATION AND  
TECHNOLOGY PARK  
港深創新及科技園

## A PLACE WHERE CROSS BORDER COLLABORATIVE INNOVATION IS REDEFINED

Boasting its unprecedented strategic location in Lok Ma Chau Loop, Hong Kong-Shenzhen Innovation and Technology Park (HSITP) is the one-of-a-kind I&T park conjointly tied to Shenzhen. Harnessing the expertise and talents from both cities, HSITP takes advantage of the unique synergistic development of "One Zone, Two Parks" equipped with supportive government policies, state-of-the-art infrastructure, and pioneering research facilities.

HSITP is the destination offering infinite opportunities for business growth & success.

**Join us NOW !**



The information contained herein is for information only and does not constitute any warranty or guarantee. All information contained herein is subject to the approval of the relevant Government authorities. All data stated herein are subject to final survey. Hong Kong-Shenzhen Innovation and Technology Park Limited reserves the right to alter the specification, design and layout of the development as referred to herein without prior notice.

 [www.hsitp.org](http://www.hsitp.org)

 [leasing@hsitp.org](mailto:leasing@hsitp.org)

 2629-6822

For more information,  
please visit HSITP website





# ***Yu Wang*** 王宇

**Chairman**

**Chinese Foundation for Hepatitis Prevention and Control**

---

Dr. WANG Yu graduated from Beijing Medical University in 1982. He continued onto his graduate study at the Institute of Hepatology, Beijing Medical University from 1983 to 1989 and received his Master's and Doctorate of Medicine during this period. From 1991 to 1993, he studied at the Jichi Medical School in Japan and received a Ph.D. degree in Preventive Medicine. In 1999, He completed Master of Business Economics program from the Chinese Academy of Social Sciences. Starting in 1985, he had been an assistant professor, associate professor, professor, deputy director and director of the Institute of Hepatology in Beijing Medical University, specializing on hepatology and viral molecular biology.

Dr. Wang had participated in and chaired a number of national scientific and technological projects and programs, such as the Natural Science Foundation of China. He served as a committee member of the Chinese Medical Association and vice chairman of the Medical Virology Branch of the Chinese Medical Association. Since 1996, he had served as the Executive Vice-Director and Director of the Office of Scientific Research in Beijing Medical University, and Deputy Dean, School of Medicine, Peking University. From 2000 to 2003, he was appointed Deputy Director of the Center for Biological Engineering and Development, China Ministry of Science and Technology. From 2003 to 2004, he was Deputy Director of the Office of Rural and Social Development at the Ministry of Science and Technology. During June 2004 to August 2017, he was appointed as the Director of Chinese Center for Disease Control and Prevention under the Ministry of Health, China.



# ***Nisa Leung***

**Managing Partner**  
**Qiming Venture Partners**

---

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 530 portfolio companies.

She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan & Lee (SSE:603087), Venus MedTech (HKSE:2500), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR), Recursion (NASDAQ:RXX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.

Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.

Nisa has been recognized by the Forbes Midas List for five consecutive years in 2019, 2020, 2021, 2022 and 2023, and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021) and Most Powerful Women in Business by Fortune China in 2022.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited ("HKEX"), Board Member of Hong Kong Palace Museum, Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA.

Partner with healthcare industry leaders?

As an integrated solutions provider?

To improve the quality of care across Asia?

Beijing

Shanghai

Macau Hong Kong

Philippines

Thailand

Malaysia / Brunei

Singapore

Indonesia

# Our Expertise. Your leading healthcare partner in Asia

Auriga is an Asian-based integrated market services provider specialising in healthcare. We aim to connect the world's leading healthcare and life sciences companies to care providers and patients across Asia with a comprehensive range of responsible and effective market management solutions.

For over 50 years, we've helped our partners bring essential pharmaceutical and life science offerings to Asia with

ethical integrity, partnership and transparency. Offering both commercial, logistics and state of the art cold chain solutions, Auriga has operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam, and the Philippines. In alignment with our mission to enrich lives with quality care, we distribute more than 500 brands at over 10,000 points of sale.





# **Akihiko Kondo** 近藤昭彦

**Vice President and Professor  
Kobe University**

---

Akihiko Kondo received his Ph.D. from Kyoto University in Chemical Engineering (1988). He has started his faculty career in 1988 in Department of Applied Chemistry at Kyushu Institute of Technology. He was appointed as full professor of Kobe University in Department of Chemical Science and Engineering in 2003 and also appointed as a team leader at RIKEN Center for Sustainable Resource Sciences (CSRS) in 2012. He was appointed a dean of Graduate School of Science, Technology and Innovation at Kobe University in 2016. He became a member of Science Council Japan in 2017 and deputy director of RIKEN CSRS in 2020 and Vice President of Kobe University in 2021.

A. Kondo has developed various platform technologies such as cell surface display systems, metabolic pathway design tools, metabolic analysis technologies, genome editing and long chain DNA synthesis technologies. He also has applied these platform technologies for construction of various microbial cell factories for production of biofuels and various chemicals from biomass, and cyanobacteria and microalgae for production of oil and chemicals from CO<sub>2</sub>. He is the scientific founder of several companies including BioPalette (genome editing), Synprogen (genome synthesis), AlgaeNexus (microalgae) and Bacchus Bio innovation (Biofundry).

He has published more than 750 peer reviewed international papers.

# We've been at this for **10 years**

## **Pioneering mRNA for over a decade**

Moderna has been advancing its mRNA platform and pipeline of medicines for more than 10 years

## **New medicines on the horizon**

Currently, **Moderna has 48 mRNA programs in its pipeline** and 35 development candidates in active clinical trials

## **Empowering scientists**

mRNA access, a global program launched by Moderna, helps to build a community of scientists who can access our mRNA technology in order to develop new medicines and vaccines



# ***Raju Kucherlapati***

**Paul C. Cabot Professor of Genetics & Professor of Medicine  
Harvard Medical School**

---

Since 2001 Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).

Dr. Kucherlapati received his Ph.D. from the University of Illinois at Urbana and did his post-doctoral work at Yale University. He was assistant professor in the Department of Biochemical Sciences at Princeton University, and then became professor in the Department of Genetics at the University of Illinois College of Medicine. In 1989 Dr. Kucherlapati went to the Albert Einstein College of Medicine where he was the Lola and Saul Kramer Professor of Molecular Genetics and University Chairman of the Department of Molecular Genetics, a position he held for eleven years.

Dr. Kucherlapati contributed to several different areas of research. These include gene targeting and homologous recombination, human gene mapping, and generation of physical maps of the human genome with special emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning many human disease genes He was a member and Chair of several review committees at the NIH, was a member of the National Advisory Council for Human Genome Research at the National Human Genomics Research Institute, and was a co-chair of the steering committee for the National Cancer Institute's Mouse Models for Human Cancer Consortium. He served on the editorial board of the New England Journal of Medicine and was editor in chief of the journal Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. Dr. Kucherlapati was a member of the Presidential Commission for the Study of Bioethical Issues during the Obama administration.

Dr. Kucherlapati was a Founder of several biotechnology companies including Cell Genesys, Abgenix (acquired by AMGEN) and Millennium (acquired by Takeda). He serves on the Boards of several privately held biotechnology companies and is a Board member of a publicly traded company called Puretech Health that trades on the London Stock Exchange. He has been active in promoting Precision Medicine in China and is the co-Chair of the International Cancer Precision Medicine Conference that just held its fourth annual meeting in Chongqing.

# BIOHK AUDITORIUM | BIOHK 會堂

## Cancer Research and Drug Development

Thursday, September 14 | 10:30 AM - 17:30 PM (GMT+8)

11:00 - 12:00	<b>Opening:</b> Dr. Sujuan Ba, Asian Fund For Cancer Research <b>Moderator:</b> Dr. Da Liu, CR-CP Life Science Fund
	<b>WT1 Cancer Vaccine for Treatment and Prevention</b> Prof. Haruo Sugiyama, Osaka University
	<b>DNA Methylation in Health and Disease; Implications for Early Prediction, Prevention and Intervention</b> Prof. Moshe Szyf, HKG Epitheraapeutics Inc.
12:00 - 13:00	<b>Expanding the Reach of Precision Medicine in Lung Cancer</b> <b>Moderator:</b> Prof. Bruce Johnson, Dana-Farber Cancer Institute
	<b>Cancer therapeutic development: Hope for the Hopeless</b> Prof. Lei Zheng, Johns Hopkins University
	<b>Precise Medicine-driven management for Primary Liver Cancer</b> Prof. Ming Kwang, Sun Yat-sen University
13:00 - 13:15	Prof. Ava Kwong, The University of Hong Kong
13:15 - 14:00	<b>Lunch Break</b>
<b>Session Two: BRACE Award Presentations</b>	
14:00 - 14:10	<b>BRACE Award Introduction</b> <b>Opening Remarks:</b> Dr. Sujuan Ba, Asian Fund for Cancer Research
14:10 - 14:20	<b>Moderator:</b> Dr. Raju Kucherlapati, Harvard University
14:20 - 14:40	<b>Circulating CDH17 Marker Made Early Screening of Colorectal Cancers and Polyps Possible</b> BRACE Awardee 2020: Dr. John Luk, Arbele Ltd.
14:40 - 15:00	BRACE Awardee 2019: Dr. Ignacio Asial, DotBio Pte. Ltd.
15:00 - 15:20	<b>Molecular Glue Degradator Drugs for Undruggable Disease Targets, Discovered by Degron's Novel Glue Discovery Platform</b> BRACE Awardee 2023: Dr. Lily Zou, Degron Therapeutics
15:20 - 15:30	<b>Coffee Break</b>
<b>Session Three: Emerging Oncology Companies</b>	
15:30 - 17:30	<b>Moderator:</b> Dr. Mark Tang, Good Health Capital <b>Empower Patients Participation in Clinical Cancer Research</b> Ms. Rose Wang, 1104 Health
	Dr. Shane Burgess, Treadwell Therapeutics Inc.
	<b>Oncolytic Virus, the Challenge and Breakthrough</b> Dr. Grace Zhou, ImmVira Pharma Co., Ltd.
	Dr. Dajun Yang, Ascentage Pharma
	<b>一种新型BRAF抑制剂ABM-1310的1期多中心开放标签研究 BRAF突变实体瘤的成年患者</b> Dr. Zane Yang, ABM Therapeutics

\*No biography or information was provided before September 01, 2023.

Sponsored by





# KOLN3D

科能三維技術(醫療)有限公司

人工骨 | 手術導板 | 訂製器具

- ✓ 骨癌治療方案
- ✓ 創傷治療方案
- ✓ 醫工合作，一站式訂製生產
- ✓ 增材製造，環保高效

獨家註冊金屬粉材

KOLN3DCobaltChrome (鈷鉻合金)  
KOLN3D316LM (316不銹鋼)  
KOLN3D Ti-6Al-4V Grade 23 (鈦合金)


- ✓ 生產廠房具有 ISO 13485:2016 認證
- ✓ 金屬粉材通過 ISO 10993-4,5,6 認證
- ✓ 產品及技術已獲中、日、韓、德等多國專利

Hong Kong innovator steps  
into Central Asia

香港創新者邁入中亞




香港創新者邁入中亞，科能三維技術(醫療)有限公司與哈薩克斯坦合作，為當地患者提供先進的醫療解決方案。該公司利用其先進的3D打印技術，為患者提供個性化的醫療器械，顯著縮短了手術時間，並提高了手術的成功率。



阿拉木圖  
09.2022

一帶一路跨國合作: 哈薩克斯坦

骨癌治療 - 盆骨置換手術



- ✓ 科能、港大、哈薩克三方攜手合作完成
- ✓ 手術時間縮短6成
- ✓ 患者9個月內恢復全負重行走 (Full weight-bearing walk)



2013年，成立於香港科學園

至今累積超過 **100** 宗成功手術個案



負載藥物骨板

DRUG CARRYING BONE PLATE (DCBP)

內建微導流滲藥系統

- ✓ 直接於傷口釋放藥物
- ✓ 有助調配最適劑量
- ✓ 高效舒緩術後痛楚

DIPLOME



榮獲2023年度日內瓦發明展金獎

medical.koln3d-tech.com



OFFICE:  
Koln 3D Technology (Medical) Limited  
Room 322, 3/F Core Building 2,  
1W Hong Kong Science Park, Shatin, Hong Kong

WORKSHOP:  
Koln 3D Medical Manufacture Limited  
Unit 402, 4/F, MARS Centre, 2 Dai Wang Street,  
Tai Po, N.T., Hong Kong

EU BRANCH:  
Koln 3D Technology SA  
Rue de la Pierre-à-Mazel 39,  
2000 Neuchâtel, Switzerland



# ***Sujuan Ba* 巴素娟**

**President and CEO**  
**National Foundation for Cancer Research**

---

Dr. Sujuan Ba has served as the President & CEO of the National Foundation for Cancer Research since 2019 and the founder & CEO of the Asian Fund for Cancer Research since 2005. Dr. Ba is a co-founder and a founding board member of the Global Coalition for Adaptive Research (GCAR), a non-profit organization pioneering the groundbreaking adaptive clinical trial platforms to deliver innovative therapies to patients faster. Dr. Sujuan Ba is also CEO & Co-founder of the AIM-HI Accelerator Fund, a non-profit organization focused on advancing oncology start-ups through venture and impact investments. She serves as a scientific advisor and a board member for more than half a dozen oncology start-ups.

Dr. Ba has served on the Women in Science Committee of CRS (Control Release Society) since 2017. She is also a Member of Springboard's Life Science Council, a group of experts worldwide in biotech, pharma, medical devices, and health IT who invest their "human capital" in Springboard's pipeline of high-growth, women-led companies. She is the former President of the Chinese Biopharmaceutical Association (2010-2011) and a lifetime member of BayHelix, an invitation-only organization of leaders of Chinese origin involved globally in life sciences and health.

Dr. Ba has led the establishment of NFCR's annual Szent-Györgyi Prize for Progress in Cancer Research, an international prize recognizing outstanding scientific achievement in the war against cancer. She has served continuously as co-chair of the Prize Selection Committee since 2006. The prize has now grown into one of the premier cancer research awards in the world.

Dr. Ba has also led the establishment of AIM-HI Women's Venture Competition in 2020, a first-of-its-kind program that provides investment, coaching, and networking opportunities to women-led oncology start-ups. More than 150 women-led oncology start-ups have gone through the rigorous review and judging process of the Women's Venture Competition platform.

Dr. Ba was awarded one of the "20 Most Inspiring Women Leaders 2022" by The Women Leaders Magazine. Dr. Ba received NBC4 WORKING 4 THE COMMUNITY Award in 2019, recognizing her outstanding achievements as a scientist, leader, and role model in the STEM fields. Dr. Ba also received the inaugural Outstanding Achievement Award from Society for Neuro-Oncology of the Chinese Medical Doctor Association for our outstanding contribution to international cooperation in 2017. She was named one of the "Top 300 Women Leaders in Global Health" in 2015 by the Graduate Institute of International and Development Studies' Global Health Programme. She was also awarded the Public Service Award in 2014 from the Chinese Biopharmaceutical Association-USA for her long-term devotion and distinguished service to the global biopharmaceutical community. She was selected to receive the CRS WOMEN IN SCIENCES Award in 2011.

Dr. Ba received her BS in radiochemistry from Peking University and her Ph.D. in chemistry from the University of Pennsylvania.



## **Haruo Sugiyama** 杉山治夫

**Professor**

**Graduate School of Medicine, Osaka University**

---

Haruo Sugiyama graduated from Osaka University School of Medicine (M.D.) and received Ph.D. degree from Osaka University in tumor virology in 1979. Then, he moved to internal medicine and specialized in immunology and hematology. He was appointed Professor, Osaka University Graduate School of Medicine in 1995 and he is now appointed Specially Appointed Professor, Osaka University Graduate School of Medicine. He discovered that Wilms' tumor gene 1 (WT1) overexpressed in almost all leukemia, and he invented WT1 mRNA assay, a clinical test that made it possible to detect only one leukemic cell in 100,000 peripheral blood mononuclear cells in 1994. This WT1 mRNA assay was covered by Japanese national health insurance for acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome (MDS), and by Chinese national health insurance for MDS. He was honored by Princess Takamatsu Cancer Research Fund Prize 2011 by the achievement of this invention. Furthermore, he discovered that WT1 overexpressed in not only leukemia but also almost all kinds of solid tumors, and he discovered that WT1 protein was a ubiquitous tumor-associated antigen (TAA) for leukemia and almost all kinds of solid tumors. And he invented WT1 peptide cancer vaccine, and he began for the first time (First - in - Human) a phase I clinical study of WT1 peptide cancer vaccine in 2002. National Cancer Institute, USA evaluated 75 popular tumor-associated antigens (TAAs) for the clinical utility, and ranked WT1 antigen as the top among the 75 TAAs in 2009. He and pharmaceutical companies are conducting many clinical studies of WT1 cancer vaccine to obtain the pharmaceutical affairs approval. Until today, over 14,000 patients with leukemia or many kinds of solid tumors were treated with WT1 cancer vaccine, including WT1 peptide vaccine and WT1 dendritic cell vaccine. Importantly, there is no WT1 vaccine-related death, and therefore, WT1 cancer vaccine is very safe. He is also trying to develop the WT1 cancer prevention vaccine for the hereditary cancer such as hereditary breast and ovary cancer syndrome and familial adenomatous polyposis caused by the mutation of tumor suppressor genes, BRCA1/2 and APC, respectively. He was honored by IAAM Innovation Award 2022 by the achievement of the development of WT1 cancer vaccine.



## **Moshe Szyf**

**McGill Professor, Department of Pharmacology and Therapeutics  
McGill University**

---

Dr Moshe Szyf is a professor of pharmacology and held a Glaxo Smith Kline and James McGill Chair in Pharmacology at McGill University in Montreal Canada and is a fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences. Szyf has pioneered research in DNA methylation for the last three decades and published more than 300 papers on the biological role of DNA methylation that span a broad spectrum from basic mechanisms to cancer diagnostics and therapeutics, as well as behavior, chronic pain and addiction. Szyf pioneered epigenetic pharmacology in cancer and as well as the field of behavioral epigenetics. Szyf studies provide a molecular link between environment and genes and between nurture and nature that had a wide impact on the social sciences and psychiatry. Szyf founded the first Pharma in the world dedicated to developing DNA methylation drugs Methylgene Inc. Szyf founded HKG epitherapeutics which develops a novel class of epigenetic diagnostic markers for early detection of cancer and other diseases.



# **Bruce Johnson**

**Professor of Medicine and Institute Physician  
Dana-Farber Cancer Institute and Harvard Medical School**

---

Bruce E. Johnson, MD, is the Co-Director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute and Co-leader of the Dana-Farber/Harvard Cancer Center Lung Cancer Program. He is a Professor of Medicine at Harvard Medical School, an Institute physician at the Dana-Farber Cancer Institute, and a Senior Advisor to the President and CEO of the Dana-Farber Cancer Institute. Dr Johnson served on the American Society for Clinical Oncology (ASCO) Board of Directors from 2008 to 2011, received their Cancer Foundation's Translational Research Professorship in 2008, and was selected as an ASCO fellow in 2012. He was elected president of ASCO for the 2017-2018 term.

Dr Johnson was one of the investigators who discovered the link between mutations of the epidermal growth factor receptor (EGFR) and sensitivity to EGFR- tyrosine kinase inhibitors and is one of the patent holders for EGFR mutation testing. He has published more than 290 research articles on a variety of topics, including the molecular basis of lung cancers and the development of targeted therapies for patients with specific genomic alterations in lung cancer.



# **Lei Zheng 郑雷**

**Professor  
Johns Hopkins University School of Medicine**

---

Lei Zheng, M.D., Ph.D. is Professor of Oncology and Surgery at the Johns Hopkins University School of Medicine. He is the Cancer Center and the Department of Oncology's Assistant Director for Translational Research and Associate Cancer Center Director for Precision Medicine. He co-leads the precision medicine research and practice at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology. He is Director for a new Multidisciplinary Gastrointestinal Cancer Laboratories Program at the Johns Hopkins Cancer Center. He is also Director of the Pancreatic Cancer Precision Medicine Center of Excellence at Johns Hopkins. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, colorectal cancer liver metastases, and gastric cancer. He is affiliated with the Tumor Immunology Program as a laboratory investigator. His primary laboratory research focus is on the identification of new targets and strategy for pancreatic cancer immunotherapies by dissecting tumor microenvironment of pancreatic cancer. He is considered to be one of world's leading pancreatic cancer oncologists and researchers and one of leading experts in preclinical and clinical development of cancer immunotherapy.

He is the founding Editor-in-Chief of Annals of Pancreatic Cancer. In 2021, he was elected into the American Society of Clinical Investigation. He served or is serving as a Councilor for Pancreatic Disorders (PAN) section of the American Gastroenterological Association Institute Council, a Member of the American Society of Clinical Oncology Grant Selection Committee and Education Committee, and a Member of the American Association for Cancer Research (AACR) Program Committee. He is also chairing the China Regional Advisory Group for the AACR International Affair Committee. He is Vice Chair of the World Association of Chinese Oncologists, is currently the Secretary General of the Committee of Oversea Experts of the Chinese Society of Clinical Oncology (CSCO), and is the Immediate Past President of the Chinese American Hematologist and Oncologist Network (CAHON). Dr. Zheng received his M.D. from Peking Union Medical College and his Ph.D. from University of Texas Health Science Center at San Antonio. He did his internal medicine training at the Long Island Jewish Medical Center (now Northwell Health and the Zucker School of Medicine at Hofstra/Northwell). He did his medical oncology fellowship training at Johns Hopkins.





HKG epi THERAPEUTICS Ltd.  
Harnessing the epigenome

# DNA METHYLATION 專利技術

- HKG EPITHERAPEUTICS LTD於2016年由加拿大麥吉爾大學MOSHE SZYF教授創辦，實驗室持有美國病理學家學會（CAP）及美國臨床實驗室改進案修正案（CLIA）雙重認證。
- MOSHE SZYF教授及其研究團隊在表觀遺傳學領域擁有近40年的經驗，專注於研究表觀遺傳學中的DNA甲基化標記。我們運用表觀遺傳學研發檢測，著重於常見疾病（如癌症）的檢測、預防及促進老年的健康生活。

• FOUNDED IN 2016 BY PROFESSOR MOSHE SZYF AT MCGILL UNIVERSITY, HKG EPITHERAPEUTICS LTD HOLDS DUAL CERTIFICATIONS FROM THE COLLEGE OF AMERICAN PATHOLOGISTS (CAP) AND THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS (CLIA). • WITH NEARLY 40 YEARS OF EXPERIENCE IN THE FIELD OF EPIGENETICS, PROFESSOR MOSHE SZYF AND HIS RESEARCH TEAM HAVE FOCUSED ON STUDYING DNA METHYLATION MARKS WITHIN EPIGENETICS. USING EPIGENETICS, WE DEVELOP TESTS WITH A FOCUS ON DETECTING, PREVENTING, AND PROMOTING HEALTHY AGING FOR COMMON DISEASES LIKE CANCER.



癌症早期檢測  
EARLY CANCER DETECTION



生物年齡檢測  
BIO-AGE DETECTION





## **Ming Kuang**

**Vice President**

**The First Affiliated Hospital, Sun Yet-sen University**

Dr. Ming Kuang is professor in hepatobiliary surgery and interventional ultrasound, and Chief of Cancer center in First Affiliated Hospital, Sun Yat-sen University. In clinical work, Dr. Kuang majors in minimally invasive treatments for liver cancer such as laparoscopic surgery, robotic surgery and image-guided tumor ablation, and he is an expert in tumor ablation with world reputation. In the field of basic research, he is interested in the mechanism, prevention and treatment of liver cancer recurrence and metastases, and precision cancer research such as immunotherapy. He has published more than 60 SCI papers in world-famous journals such as Hepatology, Cancer Letters, Radiology, Clinical Cancer Research etc. Dr. Kuang has got 7 major grants from the government, such as National Natural Science Foundation of China and Natural Science Foundation of Guangdong Province. He is vice chairman of Interventional ultrasound and Tumor Ablation Cooperation Committee in Chinese Medical Doctor Association, and chairman of Precision Medicine and Molecular Diagnosis Branch of Guangdong Medical Association.



## **Ava Kwong 鄺靄慧**

**Chief of the Breast Surgery Division**

**Queen Mary Hospital, The University of Hong Kong**

Dr. Ava Kwong is the Chief of Breast Surgery Division, Clinical Professor at the University of Hong Kong Medical Centre, Director of the Tung Wah Hospital Breast Centre and Director of Breast Center of University of Hong Kong - Shenzhen Hospital. She is the Assistant Dean (Faculty Advancement and Knowledge Exchange) of Faculty of Medicine, The University of Hong Kong. She is Honorary Consultant in Breast Surgery at Hong Kong Sanatorium and Hospital. She had also held the position of Visiting Associate Professor, Division of Oncology, at the Stanford University, USA from 2006- 2013. She has been appointed to be the co-leader of Cancer Work Group in the development of Cancer Services planning of Hong Kong West Cluster, Hospital Authority in 2012 being responsible in the planning of cancer services for the new development plan of Queen Mary Hospital and cluster. In 2013 she was elected to be the Deputy Chief and Committee Member of the Shenzhen Breast and Endocrine Cancer Society, The People's Republic of China. Aside from her clinical and academic work, she also contributes to the governmental bodies and she has also been appointed to be a member of the Cancer Coordinating Committee of the Food and Health Bureau, Government Secretariat, The Government of the Hong Kong Special Administrative Region, The People's Republic of China in August 2014. During her surgical career, she has gained multiple awards including the Hong Kong International Cancer Congress "Young Investigator Award" in 2006 and 2008 on her research work on breast cancer genetics in Chinese and Asian population, the Breast Surgery International Best Paper Prize, at the International Society of Surgery International Surgical Week meeting in 2007, and a scholarship for undertaking a research fellowship in Breast Cancer Genetics at the Stanford University School of Medicine in 2005.



## **Lily Zou**

**CEO and Co-Founder  
Degron Therapeutics**

Lily Zou is the Co-founder and CEO of Degron Therapeutics. She is a seasoned executive with comprehensive scientific knowledge in drug discovery and development and extensive business and commercial expertise. Prior to joining Degron, Dr. Zou served as CEO of Fosun Pharma USA, Vice President of Fosun Pharma Group, Healthcare Partner of Fosun Pharma, and Chairman of the Board or Board member of four companies invested by Fosun Pharma. Dr. Zou built and grew Fosun Pharma's US business and founded Fosun Pharma's incubator named Fusion Bioventures based in Boston, which invests and incubates early stage innovative biotech companies. Dr. Zou also built a sales and marketing team in the USA for Fosun Pharma drugs and diagnostics, and launched Fosun Pharma's first products in 2019. Before Fosun, Dr. Zou worked in top management consulting firm (Bain), large pharmas (Novartis/Sandoz, Wyeth, Millennium), and small biotechs (ArQule, Coley).

Dr. Zou received a BS from Beijing University, a PhD in Microbiology and Immunology from Cornell University, and a MBA from MIT Sloan School of Management.



## **John Luk 陸滿晴**

**Founder and CEO  
Arbele Ltd.**

Dr. John Luk is educated and trained at the University of Hong Kong, Karolinska (Stockholm), and Harvard (Boston). Prior to establishing Arbele, he was an academic professor for 18 years in the US, Hong Kong and Singapore, and a visiting associate professor at Harvard, adjunct professor at NUS and adjunct research director at IMCB. Through his professorship at leading institutes, he was able to establish strong scientific, clinical, and industrial networks globally. He has published around 200 papers including NEJM, Cell, Nature Medicine, and Nature Genetics. Dr. John identified and patented CDH17 at HKU (Global Licensed to Arbele). In 2011, he found his path to the drug industry at Roche and Janssen Pharmaceutical, to lead drug discovery and development programs in oncology, immunology, and hepatitis.



## **Ignacio Asial**

**Founder and CEO  
DotBio Pte. Ltd.**

Dr. Ignacio Asial is the CEO and Founder of DotBio, a Singapore-born biopharma company specialized in next-generation antibody therapies. He is also an Adjunct Assistant Professor at Nanyang Technological University.

Prior to launching DotBio, Dr. Asial held diverse scientific positions. He worked in academia in institutions such as NTU, UCSF, and Centre National de la Recherche Scientifique, as well as in the private sector at Ambrilia Biopharma and Genentech.

Dr. Asial obtained a M. Eng. in Biotechnology from Ecole Supérieure d'Ingénieurs de Luminy / Polytech Marseille, a M.Sc. in Biochemistry, Structural Biology, Bioinformatics and Genomics from Aix-Marseille University, and a Ph.D. in Biological Sciences from NTU. He specializes in technology development, in particular in the fields of antibody engineering and directed evolution.



## **Rose Wang 陸滿晴**

**Director**  
**AIM-HI Accelerator Fund**

Rose Wang is a serial entrepreneur who helps other individuals and teams—including female cancer researchers—start their own businesses and make them thrive.

Wang is the founder of Binary Group, a consulting and business solutions firm. She also currently serves as Executive Advisor to the AIM-HI Accelerator Fund, a cancer impact investment organization launched in 2019 by the National Foundation for Cancer Research (NFCR) that focuses on early stage cancer start-ups.



## **Shane Burgess**

**Chairman and Co-CEO**  
**Treadwell Therapeutics**

Dr. Shane Burgess is a Co-Founder, Chairman, and Co-CEO of Treadwell Therapeutics, headquartered in Hong Kong. In addition to co-founding several successful international companies, including FYiDoctors, Shane has held leadership roles in organizations ranging from seed-funded start-ups to leading global companies and has consistently built and led high performance teams to drive innovative product development, deliver entity-wide strategic and operational effectiveness, and achieve transformative corporate and business development results.



## **Dajun Yang 杨大俊**

**Chairman, Executive Director and CEO**  
**Ascentage Pharma**

Dajun Yang, Ph.D., is the Co-Founder, Chairman of the Board, and Chief Executive Officer of Ascentage Pharma. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D, an award widely recognized in the field drug R&D. Dr. Yang was the president of Chinese Biopharmaceutical Association-USA from 2005 to 2006 and has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, vice director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences.



# Zane Yang

**Chief Medical Officer**  
**ABM Therapeutics**

Dr. Zane Yang, a research physician with more than 20 years' experience in academic research and the pharmaceutical industry, is the Chief Medical Officer (CMO) of ABM Therapeutics.

Before joining ABM, Dr. Yang was CMO of Denovo Biopharma. During his tenure, he expanded and improved company's clinical research and development capability including two global phase 3 pivotal trials of enzastraurin in patients with newly diagnosed diffuse large B-cell lymphoma or glioblastoma multiforme. Prior to Denovo, Dr. Yang was Senior Vice President and US General Manager of Innovent Biologics. He built the company's first US R&D center and established multiple clinical trials in the US to develop sintilimab and an anti-CD47 antibody (IBI-188). Before joining Innovent, he was Senior Vice President of Clinical Research and Development for Spectrum Pharmaceuticals, where he led the entire R&D organization with a focus on developing two late-stage investigational drugs, Rolvedon (now it is approved by the US FDA) and poziotinib. In his early career years for the industry, he was Vice President, Oncology Clinical Development of Inovio Pharmaceuticals for DNA based cancer vaccine and therapy development. He also worked for Janssen Biotech / J&J Pharmaceutical Company, Novartis and Merck & Co.

Dr. Yang graduated from Peking University Medical School. Before his industry career, he was associate professor at University of Virginia Medical Center.

**BIOHK2023 CO-ORGANISER**  
**BOOTH NO. 3D-C26**



Zhejiang Difference Biological Technology is a world-class biopharmaceutical company based on recombinant virus vector technology platform, and is committed to R&D of mucosal immune vaccines, antiviral drugs high-throughput screening (HTS) system, virus vector, gene therapy, oncolytic viruses, etc.

At present, Difference is promoting 3 vaccines to IND stage - nasal influenza vaccine, nasal COVID-19 vaccine, and DIVA avian influenza vaccine. Most of the pipelines are mucosal immune vaccines, with the advantages of broad-spectrum, prevent infection for respiratory infectious diseases and more convenient to vaccination.

At the same time, Difference provides CRO services such as live imaging pharmacodynamic evaluation service, HTS system for antiviral drugs, vaccine/vector design services, IVD product development service, customized scientific research service, etc.

Company Honors : 23rd China Patent Excellence Award, National High-tech Enterprise, Hangzhou High tech Research and Development Center, Hangzhou Listed backup enterprises, Hangzhou 5050 plan

# SGS Biosafety Solutions

Health Inspired, Quality Driven.

## Our solutions

Our Center of Excellence for biosafety based in Glasgow provides:

- Electron microscopy
- GMP Sanger sequencing
- Viral vaccines Adventitious agents and species specific viruses
- Replication of competent vectors
- Retrovirus
- Process impurities
- Genetic stability
- Other microbial contaminants

## Supporting a variety of molecules

Our team of experts can support manufacturers of:

- Monoclonal antibodies
- Recombinant proteins
- Viral vaccines
- Cell therapies
- Gene therapies

"Most notably, the Biosafety Center of Excellence in Glasgow has participated in the batch-testing and release of over 3 billion doses of COVID-19 vaccine, helping to increase vaccine access and bring the global population out of the pandemic."

Archie Lovatt

Site Manager & Scientific Director at SGS

## Contact us

To discuss your biosafety requirements, contact us today.

☎ [+44 141 952 0022](tel:+441419520022)

✉ [healthscience@sgs.com](mailto:healthscience@sgs.com)

🌐 [sgs.com/services/biosafety](https://sgs.com/services/biosafety)

🌐 [sgs.com/linkedin](https://sgs.com/linkedin)

# INNOVATION GALLERIA | 創新廊

## Synthetic Biology, Cell/Gene Therapy, Globalization

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)

### Potential of Synthetic Biology in Healthcare

11:00 - 12:00

**Chair:** Prof. Fei Sun, Hong Kong University of Science and Technology

**Panelists:**

**Synthetic biology: its implications on science and biotech development in Hong Kong**

Prof. Jian Dong Huang, University of Hong Kong

**Antibody reactions and exosomes for immunotherapy and osteoarthritis treatment**

Prof. Jiang Xia, Chinese University of Hong Kong

**Precision engineering of the gut microbiome**

Dr. Lei Dai, Shenzhen Institute of Advanced Technology

### Rewrite Health with Cell/Gene Therapy

12:00 - 14:00

**Comparison of rAAV vectors manufactured by large-scale suspension cultures of sf9 and HEK293 cells**

**Chair:** Dr. Shengjiang Liu, Avirmax Biopharm Inc.

**Chair:** Prof. Xumu Zhang, Southern University of Sci&Tech

**Panelists:**

**细胞治疗产业化的机遇和挑战**

Prof. Zhang Dan, Jiangsu Hillgene Biopharma Co. Ltd

**Regulatory T cell intravitreal delivery using hyaluronan methylcellulose hydrogel improves therapeutic efficacy in experimental autoimmune uveitis**

Dr. Wai Po Chong, Hong Kong Baptist University

**Integrated CMC solution for large-scale manufacturing of biologics**

Dr. Shun Luo, Thousand Oaks Biologics

**Driving the next breakthroughs in cancer immunotherapies**

Dr. Darren Ji, Elpiscience Biopharma

**Regulatory and clinical strategy for development of second-generation gene therapy for hemophilia A**

Dr. Ruhong Jiang, ASC Therapeutics Inc.

**Less is More: Efficient non-viral immune cell engineering by circular single-stranded DNA mediated precise genomic integration**

Dr. Howard Wu, Full Circles Therapeutics\*

### Chinese Pharma Going International: Opportunities and Challenges (FDA Expert Club)

14:00 - 15:30

**Strategies of Global Collaboration and Licensing for Chinese Innovative Pharmaceutical Industry**

**Opening Speech:** Dr. Angela (Yuxin) Men, CMO for Haichang Biotech; CEO for The WhiteOak Group Inc

**Panelists:**

**Key Considerations for China Biotech's Global Collaboration**

Dr. Ning Li, Junshi Biosciences

**Decentralized Clinical Trials: Opportunities and Challenges**

Dr. Ruyi He, RemeGen Biotech

**Oversea License-out strategy of Chinese Innovative Drug Candidate**

Dr. Tao Du, Evergreen Therapeutics

15:30 - 16:30

**Strategies for Global Innovative Drug & Device Development**

**Moderator:** Dr. Angela (Yuxin) Men, CMO for Haichang Biotech; CEO for The WhiteOak Group Inc

**Panelists:**

**Key Considerations for China Biotech's Global Collaboration**

Dr. Changqing Li, Evergreen

**Decentralized Clinical Trials: Opportunities and Challenges**

Dr. Ruyi He, RemeGen Biotech

**Oversea License-out strategy of Chinese Innovative Drug Candidate**

Dr. Tao Du, Evergreen Therapeutics

Dr. Ning Li, Junshi Biosciences

Dr. Yuzhi Hu, Sidley Austin

Dr. Xiaobin Zhao, Haichang Biotech

Dr. Zhang Mingdong Suzhou SINUS MedTech

16:30 - 17:30

**Domestic Companies Going Global**

**Plenary:**

**Clinical and Regulatory Considerations for Domestic Biotech Companies Go Overseas**

Dr. Shen Xiao, 3D Medicines, Inc.

**下一代靶向CLDN18.2的抗体药物的设计及全球开发**

Dr. Xueming Qian Transcenta

**Panelists:**

Dr. Jimmy Wei, Chime Biologics

Mr. Ming Tang\*, Yunnan Baiyao Group


Ms. Shouqun Wang, China Commercial Lam Lee Lai Lawyers

Mr. Yongheng Huang\*, Guangdong Association for Standardization

Ms. Huifang Wang, Shenzhen Biotech & Industry Cleaning Association

\*No biography or information was provided before September 01, 2023.

# Innovation in Cancer Therapy



## Radioisotope produced by our linear accelerator installed near you

- New and current types of radioisotopes
- Possibility for shorter half-life radioisotopes
- Lower production / installation costs
- Increased availability
- No need to rely on imports

## Targeting Molecule

- Proven methodology to develop new molecules specific for different cancer
- Can also work with existing targeting molecules





## **Fei Sun 孫飛**

**Associate Professor**

**Department of Chemical and Biological Engineering, HKUST**

Prof. Fei Sun is an Associate Professor at the Department of Chemical and Biological Engineering, HKUST. Before joining HKUST in 2014, he worked as a postdoctoral scholar at the Department of Chemical Engineering, Caltech (supervisor: Frances H. Arnold, 2018 Nobel Laureate in Chemistry). He obtained Ph.D. in Chemistry from the University of Chicago in 2012 (supervisor: Chuan He, 2022 Wolf Prize Laureate in Chemistry) and B.S. in Chemistry from Peking University in 2007. His research interests include materials synthetic biology, protein engineering, optogenetics, chemical biology, and regenerative medicine. He is the awardee of NSFC Excellent Young Scientists Scheme (2021) and the Hong Kong RGC Research Fellow (2023).



## **Jiandong Huang 黃建東**

**Chair Professor of Synthetic Biology**

**The University of Hong Kong**

Prof. Huang earned his BS degree from Fudan University, Shanghai and went to the US through the CUSBEA program to pursue his PhD study in transcriptional regulation during fruit fly embryonic pattern formation. He earned his PhD degree from the University of California, Los Angeles. Thereafter, Prof. Huang received his postdoctoral training in mouse genetics at National Cancer Institute, NIH in the USA. During this period, Prof. Huang was the first to report that the two major intracellular transportation systems of mammalian cells, the microtubule- and actin-filament-based system directly interact with each other through their motor proteins, kinesin and myosin. Later, he established his own laboratory at the University of Hong Kong. Prof. Huang is now the Chair Professor of Synthetic Biology and the L & T Charitable Foundation Professor in Biomedical Sciences in the School of Biomedical Sciences, the University of Hong Kong.

Prof. Huang's current research focuses on two areas: synthetic biology and intracellular transportation. For intracellular transportation study, Prof. Huang has focused on illustrating the functions of a microtubule-based motor molecular, Kinesin-1, in different cell types, aiming at understanding its roles in different cell types in development and disease. For synthetic biology, Prof. Huang have created novel genetic circuits for the control of gene expression and hence biological behavior. One successful example is the design and assembly with his colleagues of a genetic circuit for the spatiotemporal control of cell distribution and function. This new circuit was used to reveal how repetitive biological structure could be generated and how the number of repeats in biological structures can be controlled. Most recently, his team further engineered the interactions among multiple cell types to generate biological structures. The abilities for spatiotemporal control of gene activities, cell-cell interactions, cell distribution and functions are very useful for future preventive and therapeutic medicine, which Prof. Huang is applying to vaccine development and cancer therapy.



## **Jiang Xia 夏江**

**Professor**

**Department of Chemistry, the Chinese University of Hong Kong**

Prof. Jiang XIA is a professor in the Department of Chemistry at the Chinese University of Hong Kong, and a professor (by courtesy) in the School of Life Sciences. Xia Jiang, graduated from the Department of Intensification of Nanjing University with a Bachelor of Science in 1999, received a Master of Science from Nanjing University in 2002, graduated from Stanford University with a PhD in 2006, and completed a postdoctoral degree at the California Institute of Technology (concurrently employed by the Howard Hughes Medical Institute).



## **Lei Dai 戴磊**

**Director**  
**Center for Synthetic Microbiome**  
**Shenzhen Institute of Advanced Technology**

---

Dr. Lei Dai is the Director of Center for Synthetic Microbiome at the Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences. Dr. Dai received B.S. in Physics at University of Science and Technology of China and Ph.D. in Physics at Massachusetts Institute of Technology. He was a Jane Coffin Childs postdoctoral fellow at UCLA School of Medicine. His research group at SIAT develops novel experimental and computational approaches to study the ecology of complex microbial communities and improve host health via precision microbiome engineering. His works have been published in *Science*, *Nature*, *Cell Host & Microbe*, *Nature Communications*, *PNAS*, etc. He is the recipient of MIT Technology Review 35 Innovators Under 35 in China.



## **Shengjiang Liu**

**President and CEO**  
**Avirmax Biopharma Inc.**

---

Dr. Liu is an experienced biotechnologist, biopharma scientist, entrepreneur and executive. After receiving his Ph.D. in biochemistry from Kansas State University and completing his post-doctoral training with Dr. Arthur Kornberg, Stanford University, he served as the group leader at Genentech Virology Research Lab. He discovered and characterized rabbit calicivirus (RCV) which caused rabbit hemorrhagic disease (RHDV) in 1984. He developed an inactivated RHDV vaccine and several fast detection methods that were effectively used for controlling and preventing RHD disease Worldwide. In 2000, he co-founded and acted as the president of Abmaxis Inc., which pioneered the breakthrough antibody engineering and production technology called Abmaxis In Silico Immunization (ASIMTM). Abmaxis Inc. was acquired by Merck Co. in 2006. Between 2006-2019, he was the Sr. Principal and Chief Scientist in Biological Development of Bayer Pharmaceuticals. He played important roles in the development and regulatory submission of 33 biologics during his biopharma career, including recombinant human factor VIII (rhuFVIII), Kovaltry®, long acting rhuFVIII-BDD (Jivi®), Rituxan® etc. Before joining Avirmax, he was actively involved in AAV-FVIII gene therapy development for hemophilia A. Now he is focusing primarily on AAV capsid & GOI engineering, payload innovation, development, and production for ocular disorders.



## **Xumu Zhang**

**Professor of Chemistry**  
**Southern University of Sci & Tech**

---

Professor Xumu Zhang has published more than 350 academic articles in academic journals including *Science*; *J. Am. Chem. Soc.*; *Angew. Chem.* His papers are cited more than 15,000 times, of which a single paper is cited more than 1300 times and his H index is over 75. Professor Zhang received the Arthur C. Cope Scholar Award from the American Chemical Society in 2002 and was the first mainland Chinese scientist to receive this award. The Zhang enyne cycloisomerization, a named reaction, developed by Professor Zhang is crowned with his last name because of its importance. At present, less than five Chinese in the world have this honor. Professor Zhang won the title of "Shenzhen Gentleman of the Year 2016" because of his contribution to the establishment of the first research institute named after the Nobel Prize winner in China, Shenzhen Grubbs Institute.

# 科学家 企业家 梦想家的创业家园

—— 多园联动 打造世界级生物医药产业集群 ——

独栋厂房现正租售中, 公寓火热预订

厂房 建面约 1000-12000m<sup>2</sup> 星级公寓 建面约 46-60m<sup>2</sup>



## 广东医谷·南沙生命科学园

双园联动, 打造南沙生物医药前沿产业带

### 主导产业

高端医疗器械、生物科技、细胞治疗、体外诊断、疫苗、创新药、免疫治疗、基因治疗等

·南沙区首个国家级科技企业孵化器 ·已入驻企业300多家

·南沙一园总建面约18万m<sup>2</sup> ·南沙二园总建面约13万m<sup>2</sup>



实拍图



效果图



## 广东医谷·珠海生命科学园

广东省重点建设项目

### 主导产业

生物医药、高端医疗器械、生物技术等

·一桥通深圳, 一桥通港澳 ·总建面约22万m<sup>2</sup> ·配套星级公寓--雲珠閣, 筑就塔尖圈层私属地



## 广东医谷·云东海生命科学园

广东省重点建设项目

### 主导产业

创新药、疫苗、高端医疗器械、免疫治疗等

·佛北战新主园区 ·云东海生物医药产业园

·一期占地113亩, 总建面约19万m<sup>2</sup>, 预计2023年7月交付



## 广东医谷·中山生命科学园

大湾区生物医药产业创新中心

### 主导产业

重点引进生物药、细胞工程、基因治疗、免疫治疗、基因芯片、大型医疗设备、高值耗材、诊断试剂等细分领域龙头企业

·总建面约60万m<sup>2</sup> ·配备污水处理站和危险品仓库

·预计2024年2月一期交付



效果图

☎ 400-876-1199

生物医药产业生态创领者



南沙生命科学园(一园): 广州市南沙区南江二路6号 南沙生命科学园(二园): 广州市南沙区美德二路北 珠海生命科学园: 珠海高新区永创路6号 云东海生命科学园: 佛山市三水区云东海大道48号 中山生命科学园: 中山市福泽路17号

官网: www.medv.com.cn 总部地址: 广州市天河区珠江新城珠江东路30号广州银行大厦七楼

免责声明: 本宣传资料属于要约邀请, 其中对项目周边环境、交通/公共设施、政府规划、商业配套、教育资源、发展前景、区位等的展示或介绍, 旨在提供相关信息参考, 开发商对此不作任何承诺, 买卖双方的权利义务以最终订立的合同约定为准(制作时间2023年7月)。



## **Wai Po Chong 莊偉波**

**Associate Professor**  
**Chinese Medicine – Teaching and Research Division**  
**Hong Kong Baptist University**

---

Dr. Chong obtained his MPhil and PhD in Immunology from the Department of Paediatrics and Adolescent Medicine at The University of Hong Kong. He received his postdoctoral training in immunology from the National Eye Institute at National Institutes of Health (NIH) in Bethesda, MD, USA. After that, he was appointed as the Associate Professor at the Key State Laboratory of Ophthalmology, Sun Yat-sen University in Guangzhou, China. He joined the School of Chinese Medicine, Hong Kong Baptist University, as the Associate Professor in 2022.

Dr. Chong's research centers on the cellular and molecular mechanism involved in immunoregulation and autoimmunity, and discovering novel therapeutic drug for autoimmune diseases. His works on autoimmunity have been well recognized and published in prestigious journals, including Immunity, Journal of Experimental Medicine, Journal of Autoimmunity, Hepatology and Journal of Infection.



## **Dan Zhang**

**Co-founder and Co-chairman**  
**Hillgene Biology**

---

- Foreign academician of Russian Academy of Engineering, co-founder and co-chairman of Hillgene Biology
- Doctor of Medicine, Peking Union Medical College; Master of Public Health, Harvard University; Master of Management, Wharton School, University of Pennsylvania
- Director of China Pharmaceutical Innovation Promotion Association, Vice Chairman of Innovation Research and Development Service Committee
- Responsible expert of the national “13th Five-Year Plan” major New drug development plan
- Head of ICHE19 IFPMA Expert Committee, expert of NMPA ICH Working Group.
- Chief scientist of Xingwan Biology, co-founder of Kunling Medicine, former first chairman of Quintiles Greater China, senior CRO industry entrepreneur and entrepreneur
- Successful approval of domestic and foreign innovative drugs leading dozens of innovative drugs



## **Shun Luo**

**Founder and CEO**  
**Thousand Oaks Biopharmaceuticals**

---

Dr. Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company's vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of goods manufactured (COGM) per gram of recombinant protein; the paradigm-shifting technology and processes Thousand Oaks Biopharmaceuticals is innovating as an integrated chemistry, manufacturing and controls (CMC) bio-manufacturer; the dry powder cell culture media facility they are building; and the strength and extensive global experience of his leadership team at Thousand Oaks Biopharmaceuticals.



## ***Darren Ji***

**Co-founder, Chairman and CEO  
Elpiscience Biopharmaceuticals**

---

Darren is Co-founder, Chairman, and CEO of Elpiscience. Prior to co-founding Elpiscience, Darren served as Venture Partner of Lilly Asia Ventures (LAV). Before joining LAV, Darren served as the Global Head and Vice President for Asia and Emerging Markets of Roche Partnering, Roche's deal-making body that manages the company's business development. While at Roche, Darren was responsible for driving the strategy and execution of partnering activities in the territory of Asia and Emerging Markets encompassing over 100 countries. During his tenure, Darren also championed and oversaw the closing of many key transactions between Roche and partners worldwide. He managed a global team and established a strong business network in key countries like China, Japan, Korea, Australia/New Zealand, Russia, and Brazil.

An accomplished entrepreneur himself, Darren spent a long career at the Procter & Gamble Company with increasing responsibilities in drug R&D and business development. He co-founded and managed as CEO of PharmaLegacy Laboratories in Shanghai in 2008, which became a premium CRO providing high-quality drug discovery services to a global clientele. Darren has been a highly respected leader in global life sciences and a sought-after speaker in various business forums. He was also an avid community builder exemplified by one of the longest tenures as a board member of the BayHelix Group.

Darren received his medical training at China Medical University, a Ph.D. from the University of Sheffield in the UK, and an MBA from the University of Chicago.



## ***Ruhong Jiang* 姜儒鴻**

**Chairman, CEO and President  
ASC Therapeutics Inc.**

---

Dr. Ruhong Jiang, is CEO of ASC Therapeutics Inc. – a global leading company in gene therapy and allogenic cell therapy. Under his leadership, the company has successfully moved two programs into clinical stage within two years. Ruhong has held a variety of technical and managerial roles in several biotechnology/biopharmaceutical companies. Prior to starting Applied StemCell, he was general manager of MicuRx(Shanghai)Pharmaceutical, Inc. a California-based biopharmaceutical company and he set up its entire China operation. From 2005-2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-million annual budgets. Before relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then director of project management at Genaisance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology and received his M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma state University in 1997. He later went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin's lab. Dr. Jiang has published more than 40 articles in the fields of human genetics, pharmacogenetics and disease animal models. In addition, Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.



# GREEN LIFE TECHNOLOGY LTD.

## PRESENTS

Official Distributor Hong Kong



## HAB® HERRMANN - THE PIONEER IN MODERN OZONE-OXYGEN- & COLON-HYDRO-THERAPY.

**Our certified medical devices set international standards. Since 1984.**

**AS THE MARKET LEADER, WE HAVE A HIGH RESPONSIBILITY.**

HERRMANN Apparatebau GmbH(HAB®) can look back on 40 years of methodically acquired expertise in the development and manufacture of high-quality medical devices. Today, HAB® is the market leader in Ozone-Oxygen- and Colon-Hydro-Therapy. Worldwide.

What sets us apart are our constantly evolving innovations and the best possible implementation of the highest patient safety standards in our competence centre - for safe, economical and future-oriented therapies.

**PATIENT SAFETY AND COST-EFFECTIVENESS. MADE IN GERMANY.  
EVERYTHING UNDER ONE ROOF. EVERYTHING FROM A SINGLE SOURCE.**



**Hyper Medozon** *comfort*

### GREEN LIFE TECHNOLOGY LTD.

Room 917, Hewlett Centre, 54 Hoi Yuen Road,  
Kwun Tong, Kowloon, Hong Kong  
marketing@greenlifetechnology.com.hk  
showroom appointment: + 852 6276 3745



**Colon  
Hydromat** *comfort*



## **Yuxin Men 门宇欣**

**Chief Medical Officer**  
**Haichang Biotech**

---

Dr. Men joined the U.S. Food and Drug Administration (FDA) in 2003, and has served as senior/master clinical pharmacology reviewer, and team leader in the Office of Clinical Pharmacology, Center for Drug Evaluation (CDER), mainly responsible for evaluation of oncology and neurological drugs IND/NDA/BLA. In her nearly 18 years of drug regulatory career, she has reviewed/approved more than 2,000 new drug applications. She has received more than 50 awards from FDA, including Distinguished Service Award, Excellent Mentor Award, Distinguished Leadership Award and Excellent Regulatory Science Award. She has led many research projects related to drug review, won 12 FDA research grants, and participated in leading the development of several FDA guidelines. In May 2022, Dr. Men was recommended by PhIRDA to become an expert in the working group of ICH E21: Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials guidelines.

Dr. Men is the vice president of the Chinese Biopharmaceutical Association – USA, the board member and vice president of the Chinese FDA Expert Association, and she is also the member of the Federal Asian Pacific American Committee (FAPAC) and the assistant chairman of the community outreach department. She hosted and served as the organizer or lecturer for many national and international conferences and made great contributions to building a communication bridge between China and the United States in biopharmaceutical field. Dr. Men graduated from Tianjin Medical University with a bachelor's degree in clinical medicine and obtained her Ph.D degree in pharmaceutical sciences from Virginia Commonwealth University. Since July 2021, she has served as the chief medical officer of Haichang Biotech. She has also served as the CEO of its subsidiary in US, The WhiteOak Inc. since early 2023.



## **Ning Li 李宁**

**CEO**  
**Junshi Biosciences**

---

Dr. Li is responsible for formulating business strategies and managing operation of the Junshi Biosciences.

From 1997 to 2010, Dr. Li worked at US Food and Drug Administration (FDA) as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Before he joined Junshi Biosciences, Dr. Li was appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.

Dr. Li obtained his bachelor's degree in public health from Shanghai Medical College of Fudan University, the PRC in July 1984 and his master's degree in medicine from Shanghai Medical College of Fudan University, the PRC in October 1987. He obtained his Ph.D. degree in preventive medicine from University of Iowa, the US in August 1994.



# A4BEE

We deliver  
digital innovation  
for **biotech, pharma**  
and **manufacturing**.

**Connectivity  
& Integration**

**Modular  
biotech smart  
components**

**Visit  
our booth!**

**3D-B18**

**Lab retrofitting:  
Edge and IoT  
connectivity**

**Cloud  
bioprocess  
monitoring**

**AR/VR  
solutions**

**End-2-End  
software & platform  
development**

**Manufacturing  
& lab equipment**

**Control and  
Automation  
engineering**

**\$10m**

worth clients'  
projects

**80+**

projects  
in 4 years

**85%**

of clients return  
with new  
challenges

**120+**

talents  
working  
with us

**Curious?  
Contact us!**

HELLO@A4BEE.COM  
WWW.A4BEE.COM







## **Ruyi He**

**Chief Medical Officer  
RemeGen**

Dr. Ruyi He is the Chief Medical Officer of RemeGen CO., Ltd. and Chief Scientist of SDIC Fund Management CO., LTD and former Chief Scientist at the Center for Drug Evaluation at the National Medical Products Administration (NMPA). Dr. He joined NMPA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the Division of Gastrointestinal and Coagulation Drug Products and later served as the Acting Deputy Director in the division for years. Dr. He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. and received his clinical and research training at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. He is a licensed, board-certified physician in Internal Medicine in the USA.



## **Tom Du 杜涛**

**Chairman  
Evergreen Therapeutics Inc.**

Dr. Tom Du graduated from Tianjin Medical University and received his PhD from McGill University in Canada. He received two years of post-doctoral training at Harvard University in the United States, under professor Frank Austen, member of the National Academy of Sciences. Since 1994, he has served as a new drug reviewer for FDA for 7 years. After joining FDA in late 2000, he served as the Director of The Registration Division of United Healthcare Corporation in the United States and senior Director of Clinical and Registration Division of Hutchison Whampoa Pharmaceuticals in Hong Kong. Since then, he has served as Humphrey's chief pharmaceutical development consultant in Humphrey Medical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete more than 100 new drug development and application work. He is currently a visiting professor of Peking Union Medical College, president of FDA Society and president of the Association of Regulations and Agreements.



# *Yuzhi Hu* 胡育志

**FDA Attorney**  
**Sidley Austin LLP**

---

Dr. Yuzhi Hu was a senior policy advisor at the U.S. Food and Drug Administration (FDA) from 2014 – 2022. As a pharmacist and epidemiologist by training and veteran FDA staff, Yuzhi focused on clinical trial evaluation and policy at the Center for Device and Radiological Health (CDRH). He led teams reviewing marketing application and postmarket oversight and compliance of devices in all therapeutical areas and submission types including PMA, 510(k), De Novo, HDE, PAS, and 522 mandated surveillance studies. Yuzhi led the CDRH-wide Real-World Evidence program and served as a voting member at the CDRH Policy and Process Governance Board. He was often consulted internally and externally on a wide range of subjects, including clinical trial design, data integrity, relevance, reliability, registry development, breakthrough designation, regulatory compliance strategy development, and more. Yuzhi also collaborated with and brought insights to international audiences, especially the regulators and regulated entities in China. He has provided training to FDA staff routinely regarding assessment of clinical evidence in regulatory decision-making.

During his time at the FDA, Yuzhi received numerous awards including most recently the 2021 “CDRH Honor Award” and “FDA Excellence Award.” Now, as a FDA attorney at Sidley Austin LLP, Yuzhi focuses his practice on various FDA regulatory, compliance, and enforcement issues. Yuzhi brings a combination of regulatory insight and scientific rigor into the complex issues that our clients face. Yuzhi helps lifescience companies, especially those with China background, navigate the intricacy of entering the US market.



# *Shen Xiao* 肖申

**Chief Medical Officer**  
**3-D Medicines**

---

20 years review experience at the US. Food and Drug Administration (FDA). At the FDA, he started as a Pharmacology/Toxicology reviewer, then became a Medical Officer after passing the US Medical Licensing Examination and was later promoted to Senior Medical Officer. He has provided non-clinical and clinical reviews for several hundred INDs including all the stages of the drug development process. He has also reviewed and approved more than ten NDAs/BLAs as a primary clinical reviewer and as a multi-discipline review team leader.

Prior to FDA, as an attending physician in Nephrology in China and research fellow in US, he had more than ten years of experience in clinical nephrology practices, studies in pharmacokinetics and dose regimens of various antibiotics in dialysis populations, and research in cellular signal transduction in various endothelial and epithelial cells under different human pathological conditions. He has received several scientific awards including the Excellence in Analytical Science Award by CDER/FDA, Hoechst Marion Roussel Excellence in Renal Research Award by the American Physiological Society, Young Investigator Award by Japan National Society of Dialysis and Artificial Organs, Young Investigator Travel Grant by International Society of Nephrology, China National Scientific and Technological Third Award, and more.

He obtained his PhD in Renal Physiology and Cell biology from West Virginia University Graduate School of Health Science Center. He had his postdoctoral training from Department of Nephrology, Johns Hopkins University, and the Department of Cardiology, University of North Carolina prior to joining in FDA.

## 生物谷

生物谷一直深耕于生物医药领域，在生物行业有着极高用户关注度与知名度。生物谷网站（[www.bioon.com](http://www.bioon.com)）资讯内容包括医药产业、制药、转化医学、生物产业、生物研究、医疗健康、医疗器械等热门主题。依托互联网，面向企业和研究机构，提供全面的咨询，行业分析服务，针对行业不同的人群进行服务细分，提供领先、精准、高效地服务体系 and 解决方案。

生物谷会议聚焦“新发现，新技术，新产业”。特别在转化医学方面，重点推动科研学术与临床应用结合，将最新的理论，医学手段与技术与临床实践结合。自成立以来，每年举办近百场转化医学领域的会议与培训，涉及肿瘤、心血管、内分泌代谢等领域。其中，率先在国内举办非编码RNA，生物标志物，肿瘤干细胞，下一代免疫治疗，细胞治疗，脑科学等前沿学术会议，推动相关创新性技术在临床和科研领域的普及与应用，助力中国科研与临床整体水平提升。此外，会议注重产业推进与合作交流，举办了分子诊断、生物制药、生物大分子论坛、大数据与人工智能，医用材料，健康管理等领域的盛会。

生物谷秉承专业、专注、独立的精神，以会议实际效果为根本出发点，客观、公正地推动新技术的学术交流研究与开放合作，在专家与业内均赢得广泛口碑与赞誉。至今已成功举办生物医药行业研讨会、论坛、峰会超过百场。干细胞研讨会、个体化用药前沿研讨会、POCT产业发展论坛、生物制药周、细胞治疗系列会议等已成为行业会议的标杆，为促进产学研交流合作，推动行业的发展起了重要的影响。





## **Changqing Li**

**Chief Medical Officer  
Evergreen Therapeutics**

Dr. Li graduated from the School of Medicine of Xi'an Jiaotong University, and received his master's degree in hospital management and his doctor's degree in public health from the University of Alabama at Birmingham, USA. He worked as a resident physician at the University of Chicago Medical Center for three years and was licensed as a physician in the United States and certified as a clinical pathologist. Dr. Li was a senior medical reviewer of the US Food and Drug Administration (FDA), and was the first person from mainland China who studied abroad to enter FDA clinical review as a doctor. He has experience in FDA drug review and has led the development of new drugs for a number of multinational pharmaceutical companies. Dr. Li has extensive experience developing new drugs in oncology, immunotherapy, anti-inflammatory, gastrointestinal and gynaecological diseases, and has extensive experience in Phase I to IV clinical trials worldwide. He has led hundreds of clinical trials and more than 30 new drug applications worldwide. In addition, he has extensive experience working with global drug regulatory agencies (FDA, EMEA, MHRA, Health Canada, PMDA, DCGI [India] and NMPA [China]).



## **Xiaobin Zhao 赵孝斌**

**Founder and CEO  
Zhejiang Haichang Biotech Co., Ltd.**

Ben Zhao is founder and CEO of Zhejiang Haichang Biotech Co., Ltd. (HCBio). Prior to HCBio, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded HCBio devoted to developing high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Expert Working Group (EWG) member for ICH, and an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University.



## **Mingdong Zhang 张明东**

**Chief Medical Advisor  
Suzhou SINUS MedTech Co., Ltd**

Dr. Mingdong Zhang is currently the Chief Medical Advisor for Suzhou SINUS MedTech Co., Ltd. Mingdong was the formal Chief Medical Officer and Vice President of Medical Affairs for Boston Scientific Asia Pacific, promoted from the position of Chief Medical Officer and Vice President of Medical and Regulatory Affairs for Boston Scientific Greater China in 2019. Mingdong was previously the Global Medical Director for Johnson & Johnson's electrophysiology business in Southern California. Mingdong was also a Medical Officer/Epidemiologist at the US FDA's Center for Devices and Radiological Health (CDRH) from 2007 to 2008. In his earlier career path, Mingdong spent eight years doing research at the US National Institutes of Health as a Research Fellow and Staff Scientist and the Medical School of the Chinese University of Hong Kong as a professor. During his service in CDRH/FDA, Mingdong provided medical reviews for multiple original PMAs and 510k submissions on medical devices including IVDs; led designs of post-approval studies; and performed risk assessment and health hazard evaluations of medical devices. Mingdong graduated from Shanghai Medical University with an MD and MPH in Epidemiology. He then earned his PhD in Molecular Virology from Baylor College of Medicine in Houston, Texas.



# 生物器材网

www.bio-equip.com

生物仪器、试剂、耗材和技术服务的专业信息平台



扫一扫关注微信号



BIOHK2023  
Media Partners



## 服务领域

生命科学, 医学研究, 生物制药, 生物工程, 现代农业, 食品安全, 环境监测, 公安司法等



## 产品范围

仪器设备、试剂、耗材、实验动物、细胞株、生物技术服务



## 访客来源

大学、研究所、医院、制药厂、疾控中心、检验检疫、环保、食品检测、公安、仪器生产制造、销售、代理、经销商等机构和企业

# 为生命科学服务，为优质厂商服务

35000+  
厂商用户

120万+  
产品信息

20万+  
在线询价



<https://www.bio-equip.com>



021-64166852



info@bio-equip.com



# ***Xueming Qian*** 钱雪明

**Executive Director and CEO**  
**Transcenta Holding Limited**

---

Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics.

Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).

Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder's Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR.



# ***Jimmy Wei***

**President**  
**Chime Biologics**

---

Dr. Wei, President of Chime Biologics, is a healthcare and life sciences executive with over two decades of global experience. Prior to joining Chime Biologics, Dr. Wei has led the incubation and investments activities into multiple well-known biotech companies, including Zai Lab, I-Mab, XW Labs, CMAB and JHL Biotech.

Dr. Wei was a founding partner of Pivotal Capital and I-Bridge Capital, and a partner of KPCB China Fund. Before joining KPCB, Dr. Wei was Senior Vice President and Head of Business Development at Hutchison Medipharma, where he was responsible for establishing global partnerships with several multinational pharmaceutical companies, including AstraZeneca, Johnson & Johnson, Lilly etc.

Dr. Wei graduated from North Carolina State University with PhD in biochemistry. He also holds an MBA with honors from the Darden Business School, University of Virginia, and a Bachelor's degree in Biology from Wuhan University.



# ***Yongheng Huang***

**Vice President**  
**Guangdong Association for Standardization**

---

Huang Yongheng is a professor-level senior engineer in standardization, vice president of Guangdong Association for Standardization, vice president of Shenzhen Standardization Association, professor of Guangdong Open University, visiting professor of Guilin Institute of Technology, and external tutor of Tsinghua University Shenzhen International Graduate School.



## **Shouqun Wang**

**Managing Partner**

**China Commercial Lam Lee Lai Lawyers**

Shouqun Wang, Managing Partner of China Commercial Lam Lee Lai Lawyers. She is currently a member of the Standing Committee of the People's Congress of Pingshan District, Shenzhen, Vice President of the Shenzhen Corporate Compliance Association, Secretary General of the Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurs Alliance, Executive President of the Shenzhen Qianhai Hong Kong Chamber of Commerce, and Secretary of the Shenzhen Qianhai Belt and Road Legal Services Federation. Director, Shenzhen Pioneer Demonstration Zone International Group Expert, and President of Shenzhen Pingshan District Biomedical Industry Law Research Institute.

Lawyer Wang Shouqun has been engaged in legal work for more than 20 years and is proficient in the fields of corporate compliance, financial securities, cross-border mergers and acquisitions, investment and financing, government services and dispute resolution. Established China's first Guangdong-Hong Kong-Macao partnership law firm – Huashang Lin Lili (Qianhai) Joint Venture Law Firm, and promoted the National People's Congress and the Ministry of Justice to approve the establishment of the "Qianhai Belt and Road Legal Services Federation" in Qianhai, taking the lead. The "Shenzhen Qianhai Hong Kong Chamber of Commerce" and the "Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurs Alliance" were established, and the first "Shenzhen Pingshan District Biomedical Industry Law Research Institute" was established in the country. She has successively served as legal counsel to government departments and large state-owned enterprises such as Shenzhen Qianhai Administration Bureau, Shenzhen Pingshan District People's Congress, Shenzhen Investment Holding Co., Ltd., Shenzhen Metro Group Co., Ltd., Shenzhen Talent Housing Group, etc.



## **Huifang Wang**

**Secretary-General**

**Shenzhen Biotech & Industry Cleaning Association**


Wang Huifang holds a PhD from the School of Basic Medicine (Pharmacy) at Guangzhou University of Chinese Medicine, an MBA from the School of Business Administration at Dalian University of Technology, a bachelor's degree in pharmacy from Henan University of Traditional Chinese Medicine, and a PHARMACY TECHNICIAN diploma from Auckland University of Technology in New Zealand.

She is currently a deputy to the Second People's Congress of Pingshan District, Shenzhen City, the Secretary-General of Shenzhen Biotech & Industry Cleaning Association, and the founding and current Secretary-General of Shenzhen Pingshan District High-Level Talents Association. She has successively served as the after-sales service manager of the marketing department of Shenzhen Joicare Group, the pharmaceutical sales manager of the marketing department of Sinopharm Shenzhen Zhijun Pharmaceutical Co., Ltd., the purchasing department manager of Sinopharm Shenzhen Jianfeng Pharmaceutical Company, the pharmacist assistant of NEW PHARMACY pharmacy in New Zealand, and the Shenzhen Enterprise Alliance Subsidiaries of the Association/Shenzhen Entrepreneurs Association: General Manager and Legal Person of Shenzhen Qilian Sanhui Economic and Trade Development Co., Ltd., Executive Deputy Secretary-General of Shenzhen Enterprise Federation/Shenzhen Entrepreneurs Association, China Joint Venture Company of Oxford University Science and Technology Innovation Center in the UK: Executive President of Shenzhen Zhongjin International Technology Transfer Center and Executive President of Shenzhen Pharmaceutical Industry Association.

Dr. Wang Huifang has worked in the pharmaceutical field for nearly 30 years and has been engaged in industry association services for nearly 10 years. She is familiar with high-level talent services in various fields. She has led the release of 5 industry group standards, including "Clean Engineering Project Quotas" and the supporting "Clean Engineering Projects" "Quota Supporting Pricing Software" has made great contributions to promoting the development of the clean industry; compiled the "Clean Industry Blue Book" to fill the gap in China; coordinated government functional departments, organized universities, law firms, and leading Chinese companies to promote the "Shenzhen Special Economic Zone" Legislate the Regulations on the Development of Clean Industry; cooperate with universities and relevant government departments of vocational education to promote the training and level evaluation of clean engineering technicians to help the high-quality development of China's clean industry; be familiar with GMP, GLP, GSP and other relevant laws and regulations in the pharmaceutical field, and specialize in medicine, Full-process project management of decoration and decoration of laboratories and factory clean rooms in food and other fields.

**BOOTH NO. 3D-A26**

# Improving Lives Through Logistics



NAF Pharma is a GDP-certified logistics provider specializing in storage and shipping of pharmaceutical, biotechnology and life sciences products.



## Our Services

We use a risk-based approach for every shipment and carry out industry best practices.

## Thermal Packaging Solutions

Our active and passive packaging covers the following temperature ranges:

- ✓ -196°C Liquid Nitrogen (LN<sub>2</sub>) / Dry Shipper
- ✓ -20°C frozen
- ✓ +2°C to +8°C refrigerated
- ✓ +15°C to +25°C controlled ambient
- ✓ Dry Ice



Cell and Gene Supply Chain



Clinical Trial Logistics



Pharmaceuticals and APIs



Biological and Infectious Substances



Biopharma and Medical Devices



Warehouse & Distribution



# TECHNOLOGY HALL | 科技廳

## Microbiome, Novel Methods, Chinese Medicine

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)

### Understanding your Microbe Garden

11:00 - 12:00

#### Symposium:

##### A Journey from Microbiome Research to Probiotics Development

Prof. Stephen Tsui, The Chinese University of Hong Kong

WDCM serves as an information infrastructure for the exploration and utilization of microbe resources worldwide

Dr. Juncai Ma, Institute of Microbiology, CAS

##### Nano-Encapsulation and Healthy Microbiome

Dr. Joo Ann Ewe, Nano and Advanced Materials Institute (NAMI)\*

### Explore Cutting Edge Approaches to Disease Treatment

12:00 - 14:00

#### Development of Novel Drugs with Potential to Cure Type 2 Diabetes

Chair: Dr. Zhongmin Ma Revivallon Biopharmaceutical

#### Panelists:

Compound to effectively decrease A $\beta$ 42 and Tau deposition, and show multi-beneficial efficacies on treating Alzheimer's disease in mice and humans

Dr. Jinan Li, Talengen Institute of Life Sciences\*

#### Novel Lipid Nanoparticles for Nucleic Acid Therapeutic Delivery

Dr. Robert Lee Zhejiang Haichang Biotechnology

#### ILNP Formulation and Preclinical Studies of mRNA Vaccine

Dr. Xudong Yuan ACON Pharmaceuticals Inc.

#### New orally administrable peptide for treatment of diabetes

Dr. Chi Ming Wong Hong Kong Polytechnic University

Prof. Guangrui Huang Beijing University of Chinese Medicine

Dr. Hongming Hu ImmuXell\*

Dr. Percy Luu, Incando Therapeutics\*

### Chinese Medicine Special Program: From Farm to Pharm

14:00 - 14:30

**Keynote Speaker:** Prof. Anlong Xu, Beijing University of Chinese Medicine\*

14:30 - 15:00

**Keynote Speaker:** Prof. Clara Lau, Chinese University of Hong Kong  
Key Considerations for China Biotech's Global Collaboration

15:00 - 17:00

**Chair:** Prof. Vivian Wong The University of Hong Kong

#### Panelists:

Prof. Wendy Hsiao Macau University of Science and Technology

From integrative medicine to new medicine by using advanced biotechnology

Prof. Aiping Lyu Hong Kong Baptist University

#### Material Innovation for Chinese Medicine Modernization

Dr. Erik Ko Nano and Advanced Materials Institute (NAMI)

17:00 - 17:30

**Sponsored Event:**  
**Bain & Company Special**

\*No biography or information was provided before September 01, 2023.

## Promoting Healthy Living by Advanced Materials & Nanotechnologies 以先進材料及納米技術促進健康生活

Nano and Advanced Materials Institute (NAMI) has established several core platform technologies for the development of marketable products in four main areas: HomeCARE, PersonalCARE, MedicalCARE, and FoodCARE, to support the industry for the development of innovative products.

納米及先進材料研發院 (NAMI) 建立了多項核心平台技術並在四個主要領域：家居護理、個人護理、醫療護理和食品護理·開發可商品化的技術·支持業界推出創新產品。

Ultra-Sensitive  
Diagnosis Technology  
超靈敏診斷技術



Tunable Hydrogel  
特性可調水凝膠



Healthcare  
Nanofiber Technology  
醫療保健納米纖維



Encapsulated Probiotics  
(Topical and Oral)  
包裹益生菌 (外用及口服)



3D Printable  
Formulations for  
Texturized Food  
3D打印配方製作具質感的食品

Highly Efficient  
Extraction Technology  
高效萃取技術

Film-Forming Technology  
薄膜形成技術



Antimicrobial Technologies  
抗菌技術



Functional Surface  
Treatment  
功能性表面處理



Sustainable Plastics &  
Functional Elastomers  
可持續塑料·功能性彈性體





## **Stephen Tsui 徐國榮**

**Professor**

**School of Biomedical Sciences, The Chinese University of Hong Kong**

TSUI Kwok-Wing Stephen is currently a Professor and the Associate Director (Research) in the School of Biomedical Sciences. He is also the Director of Hong Kong Bioinformatics Centre in the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus and facilitated the emergence of real-time PCR assay for the virus. Totally, he has published more than 270 scientific papers in prestigious international journals, including Nature, Nature Machine Intelligence, New England Journal of Medicine, Lancet, Journal of Allergy and Clinical Immunology, Allergy, Nucleic Acids Research, Genome Biology and PNAS. His h-index is 45 and the citations of his publications are over 17,000. His major research interests are next generation sequencing, bioinformatics and metagenomics in human diseases. Recently, he finished many high-quality genomes of mites and cockroach. Moreover, larger number of novel allergens in these two groups of species is identified and characterized. In 2018, he found BioMed Technology Holdings Limited in the Hong Kong Science and Technology Park. This company focuses on microbiome testing and probiotics development.



## **Juncai Ma**

**Director, World Data Center of Microorganisms**

**Institute of Microbiology, Chinese Academy of Sciences**

Dr. Juncai Ma graduated from Biological Resource Department of Mie University, Japan in 2006, is the Assistant Director of Institute of Microbiology, CAS (IMCAS) and the Director of Information Network Center, IMCAS. He is also the Deputy Chairman of the Expert Committee on CAS Database, Director of Committee on Type Culture Collection, CAS, commissioner of CODATA Chinese National Committee, and executive of WFCC. Currently he is mainly engaged in the research work on bio-grid, parallel indexing, super large-scaled full-text retrieval technology, search engine of remote heterogeneous databases, Linux Cluster System, and comprehensive utilization of IT technology in the field of biology. Meanwhile, he is in charge of the implementation of such significant projects as China Microbial Resource Database, Information Network System of CAS Biology Specimen Museum, Microbial Information Gateway of National Scientific Digital Library, E-Science Bio-Grid, National Scientific Data Sharing Platform as well as Information Network of Chinese Biotechnology and Industry.



## **Ewe Joo Ann 尤茹艷**

**Technical Manager**

**Nano and Advanced Materials Institute (NAMI)**

Dr. Joo Ann EWE has extensive research experience in probiotics and microbiome related health management. She advocates the importance of a balanced microbiome for overall gut and skin health; her research specializes in developing related functional foods and skin care products.



## **Zhongmin Ma 马忠民**

**Founder and Chief Executive Officer  
Revivallon Biopharmaceutical Co. Ltd.**

Dr. Zhongmin Ma is the founder and Chief Executive Officer of Revivallon Biopharmaceutical Co. Ltd, a company dedicated to the development of innovative drugs with potential to cure diabetes. He is also an Adjunct Investigator of Zhuhai Fudan Innovation Institute, Fudan University. Dr. Ma has more than 30 years' experience in diabetes research and drug development. Prior to founding Revivallon, he served as the Chief Scientific Officer of Diapin Therapeutics, USA, a company to develop innovative drugs to treat metabolic diseases. Before that, Dr. Ma was a professor at Mount Sinai School of Medicine (MSSM) in New York, where his laboratory made breakthrough discoveries in  $\beta$ -cell regeneration in vivo. This groundbreaking work paved the way for developing novel drugs with potential to cure diabetes. Dr. Ma was one of the founders of Chinese American Diabetes Association (CADA) and served as the President for one term. He got his Ph. D. degree in Biochemistry from St. Louis University School of Medicine and his B.S. degree in Biology from Fudan University, Shanghai, China.



## **Robert Lee**

**Chief Scientific Officer  
Zhejiang Haichang Biotechnology Co., Ltd.**

Dr. Robert Lee currently holds the position of Chief Scientific Officer (CSO) at Zhejiang Haichang Biotechnology Co., Ltd. Previously, he served as the Kimberly Chair Professor of Pharmacy at Ohio State University. Dr. Lee is widely recognized as a prominent authority in the field of drug targeting and drug delivery systems.



## **Xudong Yuan 袁旭东**

**CEO  
ACON Pharmaceuticals Inc.**


Dr. Xudong Yuan is the founder and CEO of ACON Pharmaceuticals. Dr. Yuan obtained his PhD from the College of Pharmacy in University of Georgia. Dr. Yuan had been a professor at Nova Southern University and Long Island University doing research in siRNA and drug delivery systems. Then he transitioned from academia to the pharmaceutical industry and worked in J&J, GSK, and RB at different levels, participating in different product development. Dr. Yuan also worked in smaller biotech companies, such as NAL and iView as senior director and VP in charge of R&D, manufacturing, and clinical studies. Dr. Yuan founded ACON Pharmaceuticals in 2020, and focuses on developing siRNA, mRNA therapeutics and complex drug delivery systems, such as nanoparticles, nanocrystals, and microspheres.

# About VectorBuilder

## Overview


VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside.

## Research Vectors & Virus



Service Type	Turnaround
Vector cloning	Starting from 5 days
Plasmid DNA preparation	Starting from 1-2 days
Lentivirus	Starting from 8-16 days
Adeno-associated virus (AAV)	Starting from 8-16 days
Adenovirus	Starting from 27-39 days
MMLV & MSCV retrovirus	Starting from 8-16 days
Baculovirus	Starting from 15-22 days
Vesiculo Stomatitis virus (VSV)	Starting from 21-35 days
Herpes Simplex virus (HSV)	Starting from 28-35 days
Vaccinia virus (VACV)	Starting from 21-28 days

## CRO Services



Service Type	Turnaround
AAV Capsid Evolution	Please inquire
Mutagenesis (for Vectors)	Please inquire
AAV Biodistribution Profiling	Please inquire
mRNA Gene Delivery Solutions	Please inquire
Pooled library construction	Starting from 9-15 weeks
BAC recombineering	Starting from 35-42 days
Stable cell line generation	Starting from 9-15 weeks

## CDMO services



VectorBuilder is a full-service CDMO with extensive expertise in manufacturing GMP-grade gene therapy vectors. We support the full spectrum of vector design, production and QC needs along the entire gene therapy drug development pipeline. Our highly experienced team has worked with thousands of customers to create research-grade vectors for the early discovery stage, GMP-like vectors for the pre-clinical stage, and full GMP-grade vectors for the clinical stage.

## Features Offerings



- CRISPR Genome Editing Solutions
- shRNA Gene Knockdown Solutions
- Inducible Gene Expression Solutions
- shRNA (3+1) Virus Packaging
- COVID-19 Coronavirus Solutions

Revolutionize Gene Delivery  
from Research to Therapy



载体家



云舟生物

云舟生物科技（广州）股份有限公司

电话：020-28069042

邮箱：service@vectorbuilder.cn

网址：www.vectorbuilder.com

地址：广州市科学城掬泉路3号国际企业孵化器D区三层



## **Chi Ming Wong 王志明**

**Associate Professor**  
**The Hong Kong Polytechnic University**

Dr Wong received his B.Sc. in Biochemistry at the Hong Kong University of Science & Technology in 1997 and at the University of Hong Kong in 2003, respectively. With the support of Croucher Fellowship for Postdoctoral Research, he obtained his postdoctoral training in the laboratory of Dr. Alan G. Hinnebusch (Head of the Program in Cellular Regulation and Metabolism) at National Institutes of Health working on the mechanism of eukaryotic transcription termination (Wong et al, 2007). In 2008, he rejoined his PhD supervisor Prof Dong-Yan Jin's group to explore the role of peroxiredoxin in oxidative defense and genomic stability (Tang et al, 2009; Tang et al 2015). In 2010, with the funding supports from NIH and NSFC, he studied the mechanism of eukaryotic transcription termination and its link in RNA surveillance (Wong et al 2010; Kong et al 2014). Dr Wong joined the Department of Medicine at HKU as Research Assistant Professor in 2011 and collaborated with Prof Aimin Xu (Director of State Key Lab of Pharmaceutical Biotechnology) to explore new metabolic hormones and factors (Wong et al 2014; Lee et al 2016; Huang et al 2017).

Dr Wong is now Assistant Professor at the Department of Health Technology and Informatics of The Hong Kong Polytechnic University.



## **Guangrui Huang 黄光瑞**



**Professor, School of Life Sciences**  
**Beijing University of Chinese Medicine**

Huang Guangrui, professor and doctoral supervisor at the School of Life Sciences, Beijing University of Chinese Medicine, PhD and postdoctoral fellow at Sun Yat-sen University, visiting scholar at Yale University, winner of the Outstanding Young Talent Program of Beijing University of Chinese Medicine, standing committee member of the Drug Clinical Evaluation Branch of the Chinese Society of Ethnographic Medicine, China Biotech He is a standing committee member of the Traditional Chinese Medicine Branch of the Society of Chemistry and Molecular Biology, a member of the Traditional Chinese Medicine Supervision Research Professional Committee of the China Institute of Drug Administration, and a director of the Big Data and Artificial Intelligence Branch of the Chinese Society of Ethnomedicine. The main research direction is the research and development of new traditional Chinese medicines and mechanism exploration for the prevention and treatment of immune diseases. As the first/corresponding author, he has published in *Kidney Int*, *PNAS*, *Autoimmun Rev*, *ACS Appl Mater Interfaces*, *J Immunol*, *J Nutr Biochem*, *Front Pharmacol*, *Clin Exp Immunol*, *Mol Immunol* and other international academic journals have published more than 30 SCI-indexed papers. He has 3 authorized invention patents, co-edited 2 books, hosted 7 various scientific research projects including the National Natural Science Foundation of China, and participated in 13 national-level scientific research projects.

# LABWARE®

## LIMS for the Modern Laboratory

Automate Your Laboratory  
with the Global Leader for  
**LIMS** and **ELN**



### LabWare Pharmaceutical & Bio-Pharma Manufacturing Industry Solutions

- Comprehensive Lot QA/QC management.
- Sample, test and batch tracking with full traceability.
- Advanced Product Specification management. Automated labelling, worklists and CoA generation.
- Stability / Shelf Life studies and inventory control.
- Environmental Monitoring.
- Standards, Reagents and Consumables management.
- Instrument Calibration & Maintenance.
- Flexible integration including ERP/SAP, MES and document management systems.
- Advanced Instrument integration including seamless integration with Empower & other CDS systems.
- KPI's, Dashboards, trending and charting.
- IQ/OQ validation support.

LabWare Singapore Pte. Ltd  
Phone: +65 6924 8071  
Email: [infoAP@labware.com](mailto:infoAP@labware.com)  
[www.labware.com](http://www.labware.com)





## **Vivian Wong 黃譚智媛**

**Hon Professor**

**School of Chinese Medicine, The University of Hong Kong**

---

Dr Vivian Taam Wong is an alumna of this University and a College Fellow of three disciplines: Obstetrics & Gynaecology, Internal Medicine and Public Health. Dr Wong identified the route of transmission of hepatitis B from mother to baby and conducted a landmark trial using immunoglobulin and vaccine to prevent transmission, laying the foundation for the prevention of liver cancer in the coming decades. As Public Health Specialist for the World Bank and Chairman of the “Safe Motherhood Initiative” of the International Federation of Obstetrics & Gynaecology, Dr Wong steered the planning of policies to prevent maternal deaths in developing countries. As Hospital Chief Executive of Queen Mary Hospital, Dr Wong pioneered a number of quality improvement programmes, including the Institutional Review Board for clinical research. This ethos was turned into a Hong Kong-wide movement when she became Director for Professional Services and Medical Development at the Hospital Authority.

Working with other HKU alumni, she is actively involved in the development of the “Growing Partners” mentorship and social service project. This is yet another example of her commitment to public and social service over three decades covering women, children, handicapped, environment, health and education, in addition to leadership roles in the medical profession. Dr Wong was appointed Justice of the Peace in 1999 and awarded an Honorary Fellowship from the Open University of Hong Kong in 2006.



## **Anlong Xu**

**President**

**Beijing University of Chinese Medicine**

---

Anlong Xu was awarded a government scholarship to study in the United States after his B.S. degree from Zhongshan (Sun Yat-sen) University (SYSU) in 1985. He went to the University of Illinois at Urbana-Champaign (UIUC) in Sept. 1986 to pursue his graduate study in immunogenetics under Dr. Harris Lewin’s supervision and obtained his Ph.D. from UIUC in 1992. Dr. Xu then did his postdoctoral research in Dr. Helen M. Ranney’s lab of the Department of Medicine at the University of California, San Diego for 2 years and then joined a San Diego-based Alliance Pharmaceutical Corp from 1994-1996 and worked on new drug discovery. After 10 years of study and research work in the U.S., he joined the faculty of Department of Biochemistry at College of Life Sciences, Sun Yat-sen (Zhongshan) University, his alma mater, in 1996. Dr. Xu currently is a professor in molecular biology and immunology and President of Beijing University of Chinese Medicine (BUCM) since 2013. Before BUCM, Dr. Xu was appointed to Vice-President for research and development of SYSU in 2008 after serving as Dean of the College of Life Sciences for 9 years. Dr. Xu has published about 200 papers in peer-reviewed international journals as the corresponding author, such as Nature, Cell, N Engl J Med, Lancet, J Hepatol, Nat Cell Biol, Cell Res, Nat Commun, Genome Res, Sci Signal, Am J Hum Genet, PNAS, J Immunol, J Biol Chem. Dr. Xu is currently member of American Association of Immunologist, American Association for the Advancement of Science, Chinese Society of Biochemistry and Molecular Biology and Chinese Society of Immunology, and used to serve as President of Guangdong Society of Biochemistry and Molecular Biology and Vice-President of International Society for Developmental and Comparative Immunology. He used to serve on the Editorial Board for Annual Review of Animal Bioscience, and currently serves on the Editorial Board for the following journals: BMC Genomics, Animal Biotechnology, National Review of Sciences, and as Editor-of Chief for Journal of Traditional Chinese Medical Sciences. His main research is focusing on understanding the origin and evolution of vertebrate immune system as well as discovering new drugs based on basic researches, particularly for the immune regulation of TCM diseases.





## WELCOME HONG KONG HEXU LABEL CO., LTD.

香港和煦标签用品有限公司



## ABOUT US

### 关于我们

Hong Kong Hexu label Co., Ltd. was established in November 2008. It has been dedicated to serving clients with high-end printing and packaging needs. After more than a decade of hard work and relentless efforts, Shenzhen now has a factory covering an area of over 3,000 square meters and employs over 100 staff members.

Hexu specializes in printing adhesive labels and stickers widely used in industries such as electronics, food, pharmaceuticals, clothing, and liquor. Since its establishment, our company has taken "integrity" and "quality" as the core of the enterprise, adhering to the belief of "being honest and doing things honestly". Looking forward to the future, our company will continue to adhere to the business philosophy of "quality, efficiency, integrity, and practicality", continuously improve ourselves, surpass ourselves, and provide customers with thoughtful, enthusiastic, and high-quality services!

香港和煦标签用品有限公司成立于2008年11月，一直致力服务需求高端印刷包装产品的客户，十余年的艰苦创业和不懈努力，深圳现拥有厂房面积三千多平方米，员工人数一百多人。

和煦专业印刷不干胶类标签贴纸广泛用于电子、食品、药品、服装、酒业等行业。本公司自成立以来，以“诚信”与“品质”作为企业核心，秉承着“诚信做人，实在做事”的信念。展望未来，本公司将继续以“优质，高效，诚信，务实”的经营理念，不断完善自身，超越自我，为客户提供周到，热情，优质的服务！

## OUR CERTIFICATE


### 我们的证书

We have always adhered to the concept of environmental protection, low-carbon, and sustainability, and our production factories have obtained quality and environmental protection certificates such as ISO14001, ISO45001, ISO9001, and FCS

我们始终坚持环保、低碳、可持续发展的理念，我们的生产工厂已获得 ISO14001、ISO45001、ISO9001 和 FCS 等质量和环保证书



Contact Now:  +86 15928735857

 [lucy@hexuprt.cn](mailto:lucy@hexuprt.cn)

 +86 15928735857





## **Clara Lau 劉碧珊**

**Associate Director, Institute of Chinese Medicine  
The Chinese University of Hong Kong**

---

Prof. Clara Lau is currently the Associate Director of the Institute of Chinese Medicine and the State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants at The Chinese University of Hong Kong. Her main research areas include anti-cancer herbs/natural products, and the beneficial herb-drug combinations. She has published over 280 refereed journal articles (h-index=45), 11 book chapters, and as an editor of the book series "Natural Products Chemistry of Global Plants". She currently serves as member of ChP-USP Advisory Group on Monographs for TCM Ingredients and Products; President of GP-TCM RA; Acting Secretary-General of CGCM; Council member of MCMIA. She is also the Associate Editors of Journal of Ethnopharmacology, Journal of Traditional and Complementary Medicine (eJTCM), Consulting Editor of Pharmacological Research, and Editorial Board members of various journals related to TCM or natural products.



## **Wendy Hsiao 蕭文鸞**

**Professor  
State Key Laboratory of Quality Research in Chinese Medicine  
Macau University of Science and Technology**

---

Professor Wendy Hsiao, obtained her Ph.D. Degree from Columbia University in 1985, is an expert in cancer molecular biology, Wnt and MAPK signaling, with recent research focus on anti-cancer, cancer preventive, anti-inflammatory and anti-hyperlipidemia herbal medicines. She has published more than 70 articles in major journals including Science, Nature, Cell, Molecular Cellular Biology, Oncogene, Cancer Research, Clinical Cancer Research, Carcinogenesis, J Pathology, J Natural Products.

Currently, Professor Hsiao is carrying out several major research projects in her laboratory that include a Collaborative Research Project on "Discovery and development of biomarkers for evidence-based Chinese medicines using the proteomic technology platform" and a General Research Grant working on the anticancer effects and the underlying mechanism of a medicinal herb, Jia-gu-lan. Prof. Hsiao holds patents in US, Europe and China. In addition to her effort in TCM research, she also devotes a major fraction of her time in promoting TCM education.



## **Aiping Lyu 吕爱平**

**Vice-President (Research and Development)  
Hong Kong Baptist University**

Professor Lyu Aiping is a world-leading scientist in system medicine and aptamer-based translational medicine and drug discovery. He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.

Professor Lyu initiated the idea of using systems biology approach to identify metabolite biomarkers for subtyping RA patients with distinct clinical manifestations. His clinical research has also underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. Besides, Professor Lyu has established the China's largest biobank of rheumatic diseases in Shanghai Guanghua Hospital of Integrative Medicine. The biobank has facilitated his discovery of the molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of RA patients with elevated serum C-reactive protein.

Prof Lyu has more than 600 publications with Google Scholar H index 66, i10-index 370 and a total of over 18000 citations. Over the years, he obtained more than 60 patents from his research activities.

Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. Besides, he also currently serves as Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS. Most recently, he has been elected Foreign Member of the Academia Europaea.

He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.



## **Erik Ko 高俊熙**

**Senior Technical Manager  
Nano and Advanced Materials Institute (NAMI)**

Dr. KO leads an R&D team of ~20 researchers at NAMI, an applied R&D center funded by the Hong Kong Government. His research focuses on advancing the healthcare industry through R&D projects in natural ingredients-based formulations, cosmetics, and functional foods and beverages. He is dedicated to modernizing Chinese medicine and has invented a 1-minute herbal capsule as well as nanocarrier-based herbal skincare and haircare products, transforming advanced materials from laboratory to market.



## 公司简介

东富龙生命科学事业部，聚焦于制药、医疗行业前端技术的研究和开发，形成仪器、设备、耗材（包括耗材、试剂、填料、过滤、包材等）多维一体的一站式服务。

- 在细胞治疗领域，为免疫细胞、干细胞、肿瘤细胞疫苗等制备生产提供整体解决方案；
- 在基因治疗领域，为核酸药物（mRNA/DNA）、病毒载体药物等研发及产业化提供整体解决方案；
- 在生物样本库领域，研发自动化样本存储存储管理系统，提供细胞、组织样本库整体解决方案；
- 在耗材领域，我们已经在一次性袋子（反应袋/配液袋/储液袋）、试剂（培养基/冻存保护液）、填料、过滤（微滤/深滤/超滤/纳滤）、硬质包材形成了完善的耗材方案；
- 在消毒领域，致力于空气物表消毒、感染控制、终末消毒及多重耐药菌消毒，提供环境消毒整体解决方案。

依托东富龙集团成熟的设计、制造、工程施工及覆盖全国的售后服务能力，东富龙生命科学事业部可更快速、专业的服务于生物制药行业。

## 产品展示



GMP细胞药物制备全站



SUR一次性生物摇摆器



SuBed-C mini一次性固定床生物反应器



BRG系列生物反应器



培养基



填料



一次性使用无菌袋



过滤器

# LOCI'S SQUARE | 基因位點廣場

Thursday, September 14 | 11:00 AM - 17:30 PM (GMT+8)

## IVD Cancer Screening (Sponsored by New Horizon Health)

11:00 - 12:00

**Opening Speech:** Mr. Simon Tsoi, New Horizon Health\*

**The Path to Transform Cancer Screening in China**

Mr. Yeqing Zhu, New Horizon Health

**Reach the New Horizon of Cancer Screening - A R&D perspective**

Dr. Rita Shih, New Horizon Health\*

## Innovative Healthcare

12:00 - 13:00

Prof. Cong Yan Beijing University of Chinese Medicine

**Portable noninvasive cardiovascular analyzer**

Mr. Kin Ming Lam Sramek Insight Limited

**肠道减重新疗法—胃转流支架的前世今生**

Mr. Yuxing Zuo Tongee Medical

Dr. Qiao Jiang (LeaderMed)\*

**Technologies that make lab of the future and drive collaborative innovation**

Klaudia Kozusznik A4BEE\*

13:00 - 14:30

**GBA < > Singapore**

14:30 - 17:30


**BIOHK TOP 5 ONE'S TO WATCH PITCHING COMPETITION**  
**[Training Session]**

*\*No biography or information was provided before September 01, 2023.*

**Sponsored by**



**诺辉健康**  
NEW HORIZON HEALTH





# Yeqing Zhu

**CEO**  
**New Horizon health**

With over 15 years of experience in various leadership positions, including ebusiness, IT, sourcing, and vendor management, Mr. Zhu have developed a strong expertise in IT and digital strategies. My focus has always been on leveraging technology to drive sales, enhance operational productivity, and streamline processes. As a member of the Committee of Experts for the Ministry of Science & Technology (MOST), Mr. Zhu has actively contributed to the advancement of IT service innovation. Additionally, he hold certifications as an IT advisor for the National Development Bank and the China Banking Regulatory Commission (CBRC), demonstrating my proficiency in advising on IT matters in the financial sector. He is recognized as a distinguished expert for the National Service Outsourcing Human Resources Institute.



# Cong Yan 闫聪

**Professor of Life Sciences**  
**Beijing University of Chinese Medicine**

Mr. Yan Cong, Professor of School of Life Sciences, Beijing University of Chinese Medicine (BUCM), Doctoral Supervisor, Member of Academic Committee of BUCM, Director of Weigao Research Institute of BUCM, Member of Editorial Board of TMR Journal of Modern Traditional Chinese Medicine, Journal of Practical Clinical Medicine and other journals and reviewer of journals, Vice President of Chinese Society of Ethnomedicine, Vice President of Chinese Medicines and Drugs Quantitative and Efficacy Research Branch of China Society of Ethnomedicine, and Standing Director of Evaluation and Promotion of Appropriate Chinese Medicine Technologies of World Federation of Chinese Medical Association.

He received his bachelor's degree from the School of Physics, Peking University, PhD from the Department of Physics and Astronomy, University of Nottingham, UK, and postdoctoral work at the Sorbonne University (formerly University of Paris VI), France. He was awarded the Marie Curie Youth Research Fellowship of the European Union, participated in and was in charge of the sub-projects of the Advanced Grant of the European Research Council (ERC), and the National Research Instrumentation Development Program, etc. He has published in Chemical Society Reviews, JACS, Advanced Materials, Nano Letters and other high-level journals. He has published in Chemical Society Reviews, JACS, Advanced Materials, Nano Letters and other high-level journals, with the highest single impact factor of 40.2.

Currently at the Beijing University of Chinese Medicine, he is engaged in the construction of Chinese medicine mathematical and physical system, intelligent Chinese medicine diagnosis and treatment technology research and development, from Chinese medicine micro-nano diagnostic and treatment system, Chinese medicine intelligent manufacturing, Chinese medicine intelligent scenario application, Chinese medicine digital twin, intelligent Chinese medicine diagnostic and treatment of clinical and other five directions to promote the modernization of the Chinese medicine science, as well as Chinese medicine digital health care of the combination of industry, academia, and research into the transformation.



## ***Kin Ming Lam* 林建明**

**Founder and CEO**  
**Sramek Insight Limited**

Mr. Lam is the Group CEO of Sramek Group Inc, a premium member of the American Heart Association, a committee director of HKFSCI, a corporate member of HKBMIA and a member of HKMHDIA. He graduated from the Chinese University of Hong Kong.



## ***Yuxing Zuo* 左玉星**

**Chairman / CEO**  
**Hangzhou Tongee Medical Technology**

Yuxing Zuo, also known as 左玉星, is a highly accomplished individual with a diverse background in the medical and business sectors. He is the founder of Hangzhou Tongee Medical Technology Co. Ltd and has seven years of experience as a clinical doctor in the Gastroenterology Department. With sixteen years of expertise in sales and product management of internationally renowned endoscopic medical devices, Yuxing Zuo brings a wealth of knowledge to the industry. He is the inventor of the Chinese first Gastric Bypass Stent System and holds a bachelor's degree in Preventive Medicine from Baotou Medical College. Additionally, he has a Postgraduate Diploma in Managerial Psychology (MPSY) from the University of Hong Kong. Yuxing Zuo's entrepreneurial achievements and commitment to medical innovation highlight his dedication to improving patient care and driving advancements in gastroenterology.



## ***Jiang Qiao* 姜桥**

**Founder & CEO, Leadermed Group**

Jiang Qiao has 20+ years of industry experience and is an expert in global pharmaceutical R&D and new drug approval in China. She has multiple peer-reviewed publications, and US & China patents and is a member of the Senior Scholar -China Pharmaceutical Association. Positions held: Senior Director of Global R&D Bayer/ Sanofi US R&D Headquarters, Co-Founder ClinChoice (Fountain Medical), Board Member-ProTom.



## ***Kin Ming Lam* 林建明**

**Founder and CEO**  
**Sramek Insight Limited**

Mr. Lam is the Group CEO of Sramek Group Inc, a premium member of the American Heart Association, a committee director of HKFSCI, a corporate member of HKBMIA and a member of HKMHDIA. He graduated from the Chinese University of Hong Kong.



## ***Yuxing Zuo* 左玉星**

**Chairman / CEO**  
**Hangzhou Tongee Medical Technology**

Yuxing Zuo, also known as 左玉星, is a highly accomplished individual with a diverse background in the medical and business sectors. He is the founder of Hangzhou Tongee Medical Technology Co. Ltd and has seven years of experience as a clinical doctor in the Gastroenterology Department. With sixteen years of expertise in sales and product management of internationally renowned endoscopic medical devices, Yuxing Zuo brings a wealth of knowledge to the industry. He is the inventor of the Chinese first Gastric Bypass Stent System and holds a bachelor's degree in Preventive Medicine from Baotou Medical College. Additionally, he has a Postgraduate Diploma in Managerial Psychology (MPSY) from the University of Hong Kong. Yuxing Zuo's entrepreneurial achievements and commitment to medical innovation highlight his dedication to improving patient care and driving advancements in gastroenterology.



## ***Jiang Qiao* 姜桥**

**Founder & CEO, Leadermed Group**

Jiang Qiao has 20+ years of industry experience and is an expert in global pharmaceutical R&D and new drug approval in China. She has multiple peer-reviewed publications, and US & China patents and is a member of the Senior Scholar -China Pharmaceutical Association. Positions held: Senior Director of Global R&D Bayer/ Sanofi US R&D Headquarters, Co-Founder ClinChoice (Fountain Medical), Board Member-ProTom.



## 松山湖科学城发展集团

东莞松山湖科学城发展集团有限公司是经东莞市人民政府同意，于 2021 年 2 月成立的松山湖园区国有独资企业，注册资本金 20 亿元。

公司旨在打造松山湖科学城综合投资运营服务平台，推动科学城先进产业引育能力、高端人才承载能力、城市综合服务能力的全面提升。

## 松山湖科学智汇城

科学智汇城由东莞松山湖独有国资企业松山湖科学城发展集团规划建设，项目围绕建设高标准、高质量、高水平现代化产业园区，打造大湾区示范性园区典范，为企业的发展提供全方位的软硬件保障。

项目以发展生物医药和高端医疗器械为主，其他配套产业为补充。通过引育企业项目，吸引高层次技术人才，形成产业人才聚集的产业创新生态，构建具有影响力百亿级产业集群。



松山湖科学城发展集团  
SONGSHAN LAKE SCIENCE CITY DEVELOPMENT GROUP